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vABSTRACT
New chemotherapeutic agents are urgently needed to control the spread of 
multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of tuberculosis, 
which still remains an important public health challenge globally. Recently, 
spectinamides have emerged as a novel class of anti-tuberculosis agents that overcome 
the native drug efflux. Spectinamides bind to the 30S bacterial ribosomal subunit which 
interferes with ribosomal translocation, and ultimately results in inhibition of protein 
synthesis. They have potent ???????? activity against drug resistant ??????????????
???????????? (???), and also demonstrated sustained efficacy in ???-infected mouse 
models. Pharmacokinetic (PK)/ pharmacodynamic (PD) analyses play a critical role in 
identifying the optimum dosing regimen for new treatments. In this dissertation, I 
hypothesized that the application of translational PK/PD modeling and simulation 
techniques would facilitate rational dosage regimen design for spectinamides.
To characterize the dose-exposure-response of Lee 1810, a dose-fractionation 
study was performed in BALB/c mice infected with a low dose aerosol of ???. Dosing 
with different dosing regimens was continued for 4 weeks with two blood samples 
obtained from each mice in the last week, followed by a washout period after which the 
mice were sacrificed and the lungs removed for measurement of colony forming units 
(CFU). Drug concentrations in plasma were analyzed with a validated LC-MS/MS 
method followed by a population PK analysis which also included as anchor point the 
data of a PK study in healthy mice with intensive sampling. A model for natural bacterial 
growth in ??? infection in untreated mice was built from data on the natural history of 
??? infection in mice obtained from previously performed studies and from the literature.
Based on the individual ???????? estimates from the population PK modeling, a 
sequential PK/PD analysis was performed by linking the PK model with the bacterial 
growth model via an exposure-dependent bacterial kill function that included a sigmoid 
Emax model for describing the overall rate of change in lung CFU with different dosing 
regimens. A two-compartment model with first-order absorption was used to describe the 
pharmacokinetics of Lee 1810. The average absorption rate constant (Ka), clearance
(CL/F), volume of the central compartment (Vc/F), intercompartmental clearance (Q/F),
and volume of the peripheral compartment (Vp/F) was estimated to be 2.31 h
-1,1.17
L/h/kg, 0.435 L/kg, 0.0191 L/h/kg, and 0.161 L/kg, respectively. The inter-individual 
variability in CL/F was estimated as 19.9 %. The pharmacokinetics of Lee 1810 was 
found to be different between healthy and infected mice with the later having 56.5% 
lower CL/F, 69% lower Vc/F and 69.6% lower Q/F. The two-subpopulation model could 
successfully describe the natural bacterial growth. The replication rate constant (Krep) of 
??? was calculated as 0.0327 h-1 which is consistent with values reported in the literature. 
The death rate constant induced by the immune system (Kir) was 0.00303 h-1, cell count 
of fast growing population at the initiation of the infection (N1,0) was 1.93 Log CFU and 
maximum number of bacteria (Nmax) was 6.44 Log CFU. The inter-individual variability 
in Krep and Nmax was estimated as 70.8 % and 54.7%, respectively. The bacterial kill 
induced by the drug was described using a sigmoid Emax model. The drug effect 
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parameters (EC50), maximum kill rate (Emax) and Hill coefficient (?), were estimated as 
239 μg/mL, 11.9 h-1 and 2.40 respectively. A Hill coefficient substantially greater than 1 
is a typical characteristic of concentration-dependent killing. The concentration-
dependent killing characteristic of Lee 1810 supports its intermittent dosing. 
Poor permeability of spectinamides across the gut limits its oral use. Additionally, 
since the lungs are the main site of infection in pulmonary TB, the efficacy of lead 
spectinamide Lee 1599 was evaluated after intratracheal (IT) administration in a mouse 
model of ??? infection. A dose of 200 mg/kg TIW (3 days a week) for 28 days resulted 
in excellent efficacy with 2.2 Log CFU reduction in the lungs. Based on these 
observations, a comparative biodistribution study of Lee 1599 was performed after IT 
and SC administration in mice. Plasma and tissue samples were collected at pre-specified 
time points. The drug was extracted from plasma and homogenized tissues after protein 
precipitation and analyzed with an LC-MS/MS assay. The rate and extent of absorption 
was almost two times higher with IT as compared to SC administration. As expected, the 
highest exposure of Lee 1599 after IT administration was attained in the lungs, which 
was 2.5 times higher than in plasma. This is highly desirable as lungs are the main site of 
infection in pulmonary tuberculosis. Overall, this study supports the pulmonary route as a 
potential pathway for the treatment of tuberculosis with Lee 1599.  
Physiologically-based pharmacokinetic (PBPK) modeling and simulation is a 
powerful methodology used in support of dose selection for first-in-human studies. The 
objective was to develop a PBPK model for describing pharmacokinetics of Lee 1599 in 
rats and mice, and to extrapolate this PK behavior to humans. 10 mg/kg of Lee 1599 was 
administered intravenously to rats and 200 mg/kg subcutaneously to mice. The PBPK 
model was developed based on the observed rat plasma concentrations, physicochemical 
properties of Lee 1599, and ???????? data from its metabolism, protein binding and 
permeability. The concentration-time profile of Lee 1599 in rats was well described by 
the optimized PBPK model. The model was prospectively qualified by PBPK scaling 
from rats to mice and comparing predicted murine concentration-time profiles to 
observed plasma concentrations. This model was also successful in predicting murine PK
with observed PK parameters within two-folds of predicted values. The model predicted, 
weight normalized human clearance of 0.25 L/h/kg was as expected less than the values 
in rats (0.666 L/h/kg) and mice (1.25 L/h/kg). The PBPK model predicted, a dose of 7.5 
mg/kg and 27.5 mg/kg administered once daily via intravenous administration will be 
required to attain similar exposure as observed in mice after subcutaneous administration 
of 50 mg/kg and 200 mg/kg respectively. This model suggests that an efficacious 
systemic exposure can be achieved with daily doses feasible in humans, and may be 
useful during drug development for understanding the dose requirements for future 
human studies. 
In conclusion, translational PK/PD approaches have been successfully used for 
the further development and characterization of spectinamides leads Lee 1599 and Lee 
1810. The results from the above studies will be helpful in identifying and optimizing the 
dosing regimens which can strike a balance between bacterial reduction, adverse effects, 
and emergence of resistance.
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1CHAPTER 1.   ?TRANSLATIONAL PK/PD OF ANTI-INFECTIVE 
THERAPEUTICS*
Introduction
 The treatment options available to combat infectious diseases are becoming 
increasingly limited due to a rising incidence of resistance among bacteria against the 
currently used antibiotics. Additionally, the discovery and development of new 
antibiotics has slowed down because of limited incentives for the pharmaceutical industry 
in this therapeutic area and a high benefit-risk ratio of existing antibiotics [1]. This 
necessitates prudent use of the currently clinically available as well as newly developed 
antibiotics. One of the key requirements for preserving clinical efficacy of antibiotics and 
avoiding tolerance development is to identify the optimum dosing schedule for maximum 
bacterial kill and minimal emergence of resistance [2]. Although standard 
pharmacokinetic (PK)/ pharmacodynamic (PD) indices have been used for this purpose 
with some clinical success, this approach is associated with several drawbacks. One of 
them is the high dependence upon the minimum inhibitory concentration (MIC), which is 
limited to a single efficacy endpoint that does not take into account the entire time course 
of effect and may vary between treated individuals and bacterial strains [3].  
Translational PK/PD modeling and simulation has emerged as an alternative
strategy to characterize the relationship between dose, exposure and response for 
identifying the most suitable dosing regimen. For example, infections with 
?????????????????????????? are usually characterized by the presence of both 
multiplying and non-multiplying bacteria, and most antibiotics are usually more effective 
in killing multiplying rather than non-multiplying microorganisms. Mechanistic PK/PD 
models have successfully been applied to delineate the independent drug effects 
associated with killing of the multiplying and the non-multiplying bacterial populations 
[4]. In another example, different dosing regimens with similar exposure to colistin 
resulted in greater emergence of resistance with longer dosing intervals. Based on this 
observation, PK/PD models have subsequently been used for simulating untested dosing 
scenarios and developing an optimum dosing regimen for colistin [5]. 
It is the purpose of this review to provide an overview on the mechanism-based 
PK/PD models applied in translational PK/PD modeling for antibiotics.
PK/PD Indices
For decades, the PK/PD relationships of antibiotics have been categorized with 
three different PK/PD indices, which rely on a summary measurement of ??????? drug  
*This chapter adapted with permission. Rathi, C., R.E. Lee, and B. Meibohm, 
??????????????????????????????????????????????????? Drug Discov Today Technol, 2016. 
21-22: p. 41-49[6]. 
2exposure relative to the MIC, determined ???????? using serial dilution steps [7].  
Usually, only free rather than total drug concentrations are considered as only free drug 
which is not bound to plasma proteins exerts the pharmacological activity. Standardized 
notations for these PK/PD indices are AUC/MIC, Cmax/MIC and T>MIC. AUC/MIC is 
the ratio of area under the free plasma concentration-time curve relative to MIC, 
Cmax/MIC is the ratio of free peak plasma concentration relative to MIC, and T>MIC is 
the cumulative percentage of a time period that the free concentration is above MIC. 
Antibiotics that are classified as having their efficacy driven by T>MIC show time-
dependent killing which suggests that the antibacterial effect is at its maximum with 
concentrations just above the MIC and no further improvement in killing is obtained by 
further increasing the concentrations. Cmax/MIC best describes antibiotics which follow 
concentration-dependent killing and require maximum peak antibiotic concentration for 
maximum efficacy, whereas AUC/MIC is representative of the antibiotics which elicit 
both time- and concentration-dependent killing [3]. Although the MIC based approach 
has been widely used by clinicians for designing dosing regimens and can be useful to 
predict the effect of dose fractionation on antibacterial activity, this approach is 
associated with several limitations.
PK/PD indices rely heavily on MIC. Measurement of MIC is associated with 
substantial uncertainty and variability because of the two-fold dilution technique used for 
its assessment and the interpretation as implied binary response, which considers efficacy 
only above MIC and no killing below MIC. Furthermore, MIC varies across patient 
populations and bacterial strains, and may change with time in the same patient [8]. Thus, 
MIC-based approaches ignore the dynamics of bacterial killing with time. It is typically 
assumed that a PK/PD index determined in a preclinical species or population can be 
extrapolated to another patient population. However, PK/PD indices have been found to 
vary among different patient populations, species, and disease conditions, and one of the
reasons is associated with differences in the pharmacokinetics of the antibiotic in these 
groups [9, 10]???????????????????????????-lactam antibiotics, the PK/PD index has been 
observed to change from T>MIC to AUC/MIC as the half-life increases in renally 
impaired patients. Similarly, decreases in half-life will shift the PK/PD index from 
AUC/MIC to T>MIC [11]. Thus, the value for PK/PD indices as guiding tool for dosage 
regimen design seems questionable. 
One approach to overcome these drawbacks is the use of mechanism-based 
PK/PD modeling. Rather than relying on point estimates that integrate PK and PD factors 
of the host, the drug  and the microorganism into one index, a mechanism-based PK/PD 
model has sufficient granularity to allow adjustment to changes in one of several of the 
PK and PD parameters as needed by changing clinical situations. In addition, PK/PD 
models reflect the gradual killing effect on bacteria with changing drug exposure rather 
than dichotomous all-or-nothing effects as implied by MIC values. Finally, PK/PD 
models consider the time-courses of bacterial growth and killing in relation to time 
courses of drug concentrations rather than time-integrated measures as used for the 
indices. Overall, these advantages allow for a more flexible, realistic and dynamic 
interplay of drug, host and microorganism-related factors that are ultimately predictive of 
bacterial killing and therapeutic efficacy. 
3Mechanism Based PK/PD Modeling
Mechanism based PK/PD models take into consideration the time course of 
bacterial count based on ????????, ??????? and clinical information. These models are 
composed of three basic components: (i) a component that describes the bacterial growth 
kinetics, (ii) a component that describes the pharmacokinetics of the drug, and (iii) a 
component that integrates the effect of the drug concentration on bacterial turnover.  
Bacterial growth kinetics
 The simplest model component used for describing the bacterial growth kinetics 
consists of a single bacterial compartment with a first-order rate constant for bacterial 
Krep replication (Krep) and a first order rate constant for death of the bacteria (Krep). 
Equation 1-1 and Figure 1-1A describe the mono-exponential increase in microbial 
number seen in the absence of drug treatment [12], where N is the number of bacteria.  
??
??
= ???? × ? ?  ??? × ?        Eq. 1-1
Quite often only the net process between bacterial growth and kill is quantified, with a 
first-order rate constant Kgrowth= Krep- Kdt, also called Knet, since it is difficult to 
separately estimate both the replication and death rate constants with limited data [13]. 
The underlying assumption of this model is that the microbial population is homogenous 
having the same turnover rate constants, which is an oversimplification of the real 
scenario as microbial populations are usually known to be heterogeneous with multiple 
subpopulations with distinct metabolic states and drug resistance profiles [8]. 
In the absence of antibiotics, the bacterial number N eventually approaches a 
maximum Nmaxwhen limitation in nutrients and bacterial density limit further growth. In 
this steady-state condition there is no net change in the microbial population. There are 
three ways to describe these capacity limited growth curves:
Using a logistic growth function [14, 15]: 
??
??
= ??????? × ?1?
?
????
? × ?      Eq. 1- 2 
 Using a saturable, non-linear function [16]: 
??
??
= ??????
????? 
? × ?        Eq. 1- 3
where VGmax is the bacterial maximum growth in bacterial count per time, and N50 is N 
at which the bacterial growth is half-maximal.
4Figure 1-1. Models for bacterial growth kinetics
 A) One cell population model, B) Two cell population model with different cell growth 
status.
Abbreviations: N, Number of bacteria; Krep, first-order replication rate constant; Kdt,
first-order death rate constant; S, Number of bacteria in growing state; R, Number of 
bacteria in resting state.
5Using a model where transformation from the growing (S) to the resting stage (R)
occurs when the total microbial count approaches the stationary phase [17] (Figure 
1-1B).
??
??
= =  ???? × ? ?  ??? × ? ?  (???? ? ???)  × ?
???
????
? × ? +  ??? × ? Eq. 1- 4
??
??
=  (???? ? ???)  × ?
???
????
? × ? ?  ??? × ? ?  ??? × ?   Eq. 1- 5
where S and R are the number of growing and resting bacteria, respectively. A high total 
bacterial load is assumed to potentiate the transformation from S to R. The transfer back 
to the growing stage (Krs) is usually assumed to be negligible during ???????? time-kill 
experiments and therefore in those cases fixed to 0. 
In some instances, additional delay functions have been introduced to characterize 
the growth delay observed during the first hours after the initiation of growth experiments 
when the microbes have not yet reached the logarithmic growth phase. For example, 
inverse mono-exponential functions with asymptotic increase such as 1-e-?×t have been 
used as multiplier for Krep or Kgrowth, where ? is a first-order rate constant characterizing 
the dissipation of the delay [18, 19]. 
Pharmacokinetics
The pharmacokinetic model component is used for characterizing the 
concentration profile of a drug over a time period. Traditional compartmental modeling 
approaches are generally used to describe the pharmacokinetics with one- or multi-
compartment systems. For example, in an ???????? chemostat-based PK/PD model system
[19], the drug concentration can be described with a one-compartment model with mono-
exponential decrease with time according to
??
??
= ? ?? ×?         Eq. 1-6
where C is the concentration of the drug and Ke is the first-order elimination rate constant 
of the drug. 
The pharmacokinetic profile of a new drug is usually established in healthy 
subjects during the initial clinical phase of drug development. The pharmacokinetics may 
however be altered under pathophysiologic conditions in a diseased population. For 
example, drugs which are primarily renally cleared may reach higher systemic exposure 
in patients with renal impairment compared to healthy individuals. In these cases, 
creatinine clearance is typically found to be a significant covariate and can be used to 
guide patient customized dosing [20]. Disease conditions can also cause changes in the 
body fluids and protein binding which may ultimately affect tissue distribution and the 
6free fraction of the drug [21], and may thus need to be considered in the pharmacokinetic 
model component of mechanism based PK/PD models. 
Many microbial infections are localized in extravascular tissues rather than blood 
or plasma [22]. The concentration at the site of infection may in these cases be different 
from plasma concentrations due to drug distribution processes and may thereby 
complicate the accurate assessment of optimal dosing regimens [23]. For example, 
concentration-time profiles of antibiotics in epithelial lining fluid in the lungs was found 
to be different from plasma with concentration ratios ranging from <0.1 to 3 [24]. In 
addition to efficacy, organ or tissue concentrations may also be of interest with regard to 
toxicity [25]. Techniques like microdialysis have been used for measurement of drug 
concentrations in tissue/organs [26]. Tissue distribution of antibiotics may be predicted 
using physiologically-based pharmacokinetic (PBPK) modeling [27, 28]. Recently, a 
PBPK model incorporating a multi-compartment permeability-limited lung model was 
used to simulate the pharmacokinetics of anti-tuberculosis agents in plasma, lungs and its 
sub-compartments where the mycobacteria reside in the host [29]. This model also 
provides a framework for predicting the lung concentrations of novel anti-tuberculosis 
agents.
Pharmacodynamics 
The drug effect E can be modeled to either inhibit bacterial replication or 
potentiate bacterial killing. The relationship between drug concentration and its 
antimicrobial effect is usually described using an ordinary (???) or a sigmoidal (??1)
inhibitory Emax model. The general expression for the bacterial growth kinetics is then 
modified to Equation 1-7: 
??
??
= ???? × ????  × ? ? ??? × ??? × ?      Eq. 1-7
Drug effect decreasing the replication rate can then be modeled as 
???? = 1?
????×???
????
??????
        Eq. 1-8
Drug effect increasing the death rate can be modeled as 
??? = 1 +
????×???
????
??????
        Eq. 1-9
Here Emax and Imax represent the maximum increase or decrease in effect, EC50 and IC50
represent the concentrations of drug that produce half of Emax and Imax, and ?1 and ?2 are 
the sigmoidicity coefficients. In Equation 1-8 and Equation 1-9, the effect corresponds 
to a unitless fractional change in the rate constant with Emax and Imax representing the 
maximum achievable fractional change. 
7Alternatively to these proportional effect models, the increase in the death rate 
can also be modeled as an additive effect (Figure 1-2A):
??
??
= ????  × ? ? ??? × ? ?
????×??
????
? ???
× ?     Eq. 1-10
In Equation 1-10, the effect corresponds to an additional kill-rate constant contributed by 
the drug with Imax, representing the maximum achievable drug-imposed kill-rate constant 
having the unit 1/time. 
Combination Therapy
 Combination therapy of antibiotics has been found to be useful as it may improve 
efficacy, increase patient compliance by optimizing dosing schedules, reduce toxicity, 
and suppress the emergence of resistance [30]. There is high potential for 
pharmacodynamic drug-drug interactions when antibiotics of a combination therapy act 
on the same or different molecular targets (serial or parallel) in the same pathogen, 
resulting in additive, synergistic or antagonistic interaction [31]. The concentration-effect 
relationship for two-drug combinations results in a three-dimensional response surface 
which is usually characterized quantitatively using the response surface analysis as 
described by Equation 1-11 [32, 33]: 
? = ??
????,?×?
?
??????
?
?
??
+ ??
????,?×?
?
??????
?
?
??
+  ?×??×??
????,?×????,?×?
?
??????
?
?
???
? ????
Eq. 1-11
where C1 and C2 are the concentrations of drug 1 and drug 2 in the combination therapy; 
IC50,1 is the concentration for which the effect is half maximal for drug 1 when present 
alone; IC50,2 is the concentration for which the effect is half maximal for drug 2 when 
present alone; ?1and ?2are the sigmoidicity coefficients for drug 1 and drug 2, 
respectively; Imax is the maximum bacterial killing rate constant; ? is the interaction 
parameter; and I is the combined effect of both the drugs. The summation of the first and 
second term on the right side of the equation defines the additive effect whereas the third 
term is the drug interaction term. The combination effect is additive when ? = 0, is 
synergistic when ? >> 0, and is antagonistic when ? << 0.
The kinetics of bacterial killing for the combination therapy can then be described 
using Equation 1-12 with modification of the drug effect term by taking a similar 
approach as described above for the response surface analysis [34]. 
??
??
= ????  × ? ? ??? × ? ? ?
????× ?
??
????,?
? ??????,?? ?×
??×??
????,?×????,?
?
?
 
??? ??????,?
? ??????,?? ?×
??×??
????,?×????,?
?
? ? × ? Eq. 1-12 
8Figure 1-2. PK/PD models consisting of pharmacokinetic component, bacterial growth model, and pharmacodynamic link
A) One bacterial population with additive effect on death rate. B) Subpopulation approach for antibiotic resistance with two or more 
bacterial populations each having different drug sensitivity. C) Adaptation approach for drug resistance with adaptation factor 
modulating drug sensitivity.
Abbreviations: C, drug concentration; N/N1/N2/Nx, number of bacteria in different bacterial populations; Ke, first order drug 
elimination rate constant; Krep, first-order replication rate constant; Kdt, first-order death rate constant; Imax, maximum achievable 
effect (subscripts indicate different values for different bacterial populations); IC50, drug concentration producing 50% of Imax
(subscripts indicate different values for different bacterial populations); ?, is the sigmoidicity factor; ? , adaptation factor. 
9when ? is the interaction parameter; and ? is the sigmoidicity coefficient for the 
combination therapy, under the assumption that in the response surface analysis, ?1= ?2.
Antibiotic Resistance
Antibiotic resistance can be mathematically explained either by an increase in 
IC50 or decrease in Imax. Prior knowledge about the mechanism of resistance can be used 
as a rationale for choosing the appropriate model. When reduced drug sensitivity can 
completely be overcome with a higher dose, an increase in IC50 is suggested as the 
probable mechanism for resistance. If even high doses are unable to achieve the 
maximum effect, however, then a decrease in Imax might be the more appropriate 
mechanism [13]. 
A variety of PK/PD models have been proposed for describing antibiotic 
resistance. These models can be broadly categorized into subpopulation approaches and 
adaptation approaches. 
Subpopulation approaches
The more commonly used subpopulation approaches assume that the total 
bacterial population is composed of several discrete subpopulations with different drug 
susceptibility as shown in Figure 1-2B. These subpopulations are considered to be 
present even in the initial inoculum. Subsequent treatment with antibiotic leads to 
predominant killing of susceptible subpopulations along with selective replication of the 
less susceptible subpopulations resulting overall in regrowth. More than one differential 
equation is used simultaneously with each equation representing one bacterial 
subpopulation (often with different drug susceptibilities) [35]. A variation of the 
subpopulation model is one in which new drug resistant mutants are formed from the 
growing subpopulation with a first-order mutation rate during the experiment resulting in 
regrowth [36]. 
 A modification of the sub-population approach could potentially be used to 
facilitate development of new generation anti-infectives which do not necessarily kill the 
bacteria. For example, Bezlotoxumab, a fully human monoclonal antibody, was found to 
decrease the rate of recurrence of ????????????????????? infection in patients treated with 
standard-of-care antibiotics [37]. Bezlotoxumab acts by neutralizing the exotoxin B 
thereby averting its interaction with colonic cells and the associated inflammation. One of 
the possible approaches to characterize the PK/PD in this scenario could be a modified 
subpopulation model where the Bezlotoxumab induced toxin neutralization is modeled in 
parallel with the killing effect imposed by the standard-of-care treatment on the 
susceptible ????????????????????? population. 
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Adaptation approaches
 An alternative to the subpopulation model in which the total bacteria are assumed 
to be a mixture of different populations is the adaptive resistance mechanism in which the 
initial drug susceptible population is gradually considered to evolve into a drug resistant 
population as shown in Figure 1-2C. Only one differential equation is used to describe 
the rate of change of the total bacterial population. An adaptation factor (?) is introduced 
which may be dependent on time and concentration: 
? = 1 +  ? × (1?  ???×?×?)       Eq. 1-13
where ? describes the maximum adaptation factor and ? represents the rate of adaptation. 
Dependent on how the adaptation function is implemented in the PK/PD model, a gradual 
increase in time and concentration may result in an increase in IC50, decrease in Imax, or 
decrease in bacterial replication rate [38]. 
Identification of the true resistance mechanism based only on total bacterial 
counts and statistical modelling criteria have failed in the majority of cases. 
Quantification of resistant populations will help in distinguishing between competing 
models and support the selection of the most appropriate model for bacterial resistance 
[39]. 
Inoculum Effect
The phenomenon that when a higher bacterial density of initial inoculum in an 
experiment leads to a reduced antibacterial effect is referred to as inoculum effect [40] 
Some of the potential mechanisms for this phenomenon are (i) enzymatic inactivation of 
the drug, (ii) non-specific binding to the bacteria, and (iii) increased likelihood of the 
preexistence of subpopulations of resistant bacteria if the density of the inoculum is 
higher than the natural mutation rate of the bacteria. For example, the pharmacodynamic 
??????????????????????????-lactam antibiotic, changed from time-dependent killing to 
concentration-dependent killing when inoculum density was increased [41]. This 
conversion in the PK/PD-index has b????????????????????????????????????????????????????-
??????????????????????????????????????????????????????????????????????-lactam 
antibiotics.
Bacterial burden shows a wide variation in patients and therefore a PK/PD model 
which incorporates an inoculum effect might be more predictive in clinical scenarios. 
One of the models proposed to describe inoculum effects is based on the concept of 
quorum sensing. It assumes that all bacteria release signal molecules to communicate 
with each other which consequently results in reduced drug sensitivity [42]. 
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Host Responses
??????? models of bacterial infection are oftentimes established in immuno-
compromised animals as they allow for proper estimation of antibiotic efficacy without 
any interference from the immune system. In many cases, the PK/PD indices needed to 
be achieved for efficacy in these models are higher compared to those obtained in 
immuno-competent animals [43]. ??????? infection models in animals with functional 
immune system, although less common, have also been used for assessing the efficacy of 
antibiotics. As the immune system of immunocompetent animals has the ability to kill 
bacteria, it is important to study the time course of this effect independently from 
antibiotic therapy in order to be able to delineate the intrinsic activity of the drug from 
that of the immune system. The immune system effect can be assessed by three different 
approaches: 
Modulation of bacterial challenge  
In this approach inocula with different initial density were used in the same type 
of animal infection model to quantify the antimicrobial effect associated with the immune 
system [44]. The immune system was successful in reducing the bacterial load when the
initial inoculum was low; at higher initial inocula, however, the immune system’s 
capacity was overwhelmed resulting in net bacterial growth. This impact of immune 
system has been described quantitatively using mathematical models where the rate of 
change in bacterial count is equal to the difference between the growth rate of bacteria 
and the kill rate contributed by the antibacterial effect of the immune system [44]: 
??
??
= ??????? × ?1?
?
????
? × ? ? ????×?
?????
? × ?    Eq. 1-14
Here, Kir is the maximal kill rate induced by the immune system and N50 is the number of 
bacteria per g of tissue at which the immune-system mediated kill rate is half-maximal.
Modulation of immune reactivity
An alternative strategy to quantify the contribution of the immune system towards 
bacterial reduction is to use animal infection models with different levels of 
immunosuppression [45]. A pneumonia mouse model with functional immune system 
was treated with different escalating doses of the immunosuppressant cyclophosphamide, 
thereby reducing the neutrophil counts by 20, 70 and 90%, respectively. The rate of 
change in the bacterial count was equal to the difference between the first order growth 
rate of bacteria and the saturable kill rate attributed to the number of available 
neutrophils: 
??
??
= ??????? × ?1?
?
????
? × ? ? ? ???×???
?????????
? × ?   Eq. 1-15
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ANC is the absolute neutrophil count and ANC50 is the ANC required to achieve 50% of
maximal kill rate.
Natural progression of disease
The effect of the immune system can also be included as a time-dependent first-
order kill rate, in addition to the natural death rate as described by Equation 1-16, for 
example when immunocompetent animals are treated with vehicle control and establish 
adaptive immunity over time. This assessment may result in a slight overestimation of the 
impact of the immune system, however, if comparative data in immunocompetent and 
immune-compromised animals are not available to delineate the real immune system 
effect from natural bacterial death:
??
??
= ???? × ?1?
?
????
? × ? ? ? ???×?
?
????? ??
? × ? ?  ??? × ?    Eq. 1-16 
Here Kir is the maximum death rate constant induced by the immune system, t is the time, 
t50 is the time when the death rate constant is half of its maximum value, and ? is the 
sigmoidicity factor that determines the shape of the curve. The effect of the immune 
system is thus modeled as a gradual, time-dependent increase of the death rate constant 
until it reaches its maximum Kir.
Bench to Bedside Translation of PK/PD Models for Anti-Infectives
The current paradigm for translation of antibacterial PK/PD from preclinical 
species to humans requires integration of the PK/PD index determined in animal models 
with human pharmacokinetics [46]. Stochastic simulation of human drug exposure using 
population pharmacokinetic models generates concentration-time profiles which are then 
used to compute the PK/PD index for each simulated subject. Based on the proportion of 
subjects with the desired value of the PK/PD index, probability of attaining the 
therapeutic target is predicted. This approach helps in making decisions regarding the 
choice of dosing regimens to be implemented in the clinic.  
The use of mechanistic PK/PD models for translation from preclinical to clinical 
scenarios has been limited. PK/PD models based on ???????? static and dynamic kill 
curves have been successful in the prediction of ??????? effects in animal models [9]. 
However, there is still a knowledge gap regarding translation of PK/PD parameters from 
preclinical to clinical settings. For example, recently a multistate tuberculosis 
pharmacometric model describing different bacterial states of ??????????????
???????????? was developed based on ???????? data [4]. For clinical implementation of this 
model [47], most of the parameters pertaining to the natural bacterial growth were fixed 
to the ???????? estimates; however the exposure-response parameters related to drug effect 
had to be estimated from clinical data and were different from the ???????? drug effect 
parameters. More research efforts are needed in this area to better facilitate the 
quantitative translation of mechanistic PK/PD models to clinical situations.
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Development of a Translational PK/PD Model for Antibiotics
Mechanism-based models for antibiotics are usually established in a stepwise 
fashion, in which the different model components are individually developed and 
integrated (Figure 1-3). The typical steps include the following: 
1. Development of a pharmacokinetic model in the studied population (animal 
models or humans), that captures the time course of free, pharmacologically 
active concentrations of the antibiotic, preferably in the relevant target tissue.
2. Development of a bacterial growth model that captures the bacterial growth 
kinetics and potential host response effects.
3. Integration of the bacterial growth model and the pharmacokinetic model 
component into a PK/PD model with a pharmacodynamic model component that 
links the dynamics of drug concentrations to bacterial turnover. This may include 
drug combination models, inocula effects, and resistance development.  
Once the model has been established, it can be used for simulations to interpolate 
and extrapolate the observed experimental data to other, untested scenarios, such as 
different dosing regimens, or different patient populations [3, 48]. It can also be used for 
quantitative comparisons of multiple drug candidates to identify lead candidates and 
support go-no go decisions [8]. 
Conclusions
Mechanism-based PK/PD models are increasingly been used in developing dosing 
strategies for antibiotics in drug development and clinical application. Although these 
models are simplified depictions of rather complex interactions of drug, microbe and host 
physiologic processes, they are able to capture the time course and magnitude of 
antibacterial effect in relation to bacterial growth, the pharmacokinetic and 
pharmacodynamic properties of the drug, and the chosen dosing regimen. Complicating 
factors such as resistance development, combination therapy, or host responses can be 
incorporated in the modeling approach. In situations where only limited data are 
available, system specific parameters describing for example growth characteristics may 
also be implemented based on prior knowledge [4]. With these tools at hand, translational 
PK/PD modeling and simulation may play a pivotal role in identifying the right balance 
between bacterial killing, adverse effects, and appearance of resistance, and may help 
identifying and optimizing dosing regimens for novel and established antibacterial 
agents.
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Figure 1-3. Steps involved in the development and application of a translational PK/PD model for antibiotics
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CHAPTER 2.   ?HYPOTHESIS AND SPECIFIC AIMS
 Tuberculosis (TB) is a serious life threatening disease resulting in 1.4 million 
deaths per year. Multidrug resistant (MDR) TB (resistant to first line agents: Rifampin 
and Isoniazid) causes an estimated 300,000 deaths per year. To further exacerbate the 
situation, extensively drug resistant (XDR) TB (resistant to first line agents and at least 
one second line agent) and totally drug resistant TB (resistant to all first and second line 
agents) infections are increasing at an alarming rate in the developing world.  
The devastating socioeconomic and public health impact of tuberculosis and the 
known toxicity of many existing treatments motivated our research team to develop 
spectinamides, a series of semi-synthetic analogues of the antibiotic spectinomycin, into a 
novel class of antitubercular drugs. Spectinomycin historically has been used as a second-
line agent to treat gonorrheal infections; however, it has only limited activity against 
?????????????????????????? (???). Yet, its high safety margin and its distinct ribosomal 
binding site make it a preferred lead structure. By modifying its structure, our research 
team generated spectinomycin analogues with excellent ??????? antitubercular activity 
which bind to a unique site within the 30S mycobacterial ribosome subunit, and block 
ribosome translocation. Furthermore, it was also demonstrated that spectinamides, in 
spite of being highly hydrophilic, are extremely efficacious because in contrast to 
spectinomycin they are able to evade the efflux transporter Rv1258c expressed in ???.
These findings for the first time challenged the previous view in the field that ??? is 
intrinsically resistant to many polar antibiotics because of its waxy coating around the 
cell membrane.
Spectinamides have undergone a comprehensive lead optimization process which 
included refining the chemical structure to obtain optimum pharmacological, 
biopharmaceutic and pharmacokinetic characteristics using an iterative approach. Based 
on these evaluations, Lee 1599 and Lee 1810 have emerged as lead candidates with 
excellent antitubercular activity against both drug susceptible as well as MDR- and XDR-
drug resistant ??? strains, a high safety margin, narrow anti-microbial spectrum, lack of 
cross-resistance with other protein synthesis inhibitor, low synthesis cost, and favorable 
pharmacokinetic characteristics. The overall objective of my dissertation work is to 
utilize translational PK/PD approaches for the further advancement of spectinamide lead 
candidates, Lee 1599 and Lee 1810, into the late discovery stage. I hypothesize that 
translational PK/PD approaches facilitate the drug development process in the late 
discovery stage by providing information on optimal dose selection, rationales for route-
specific efficacy differences, and the feasibility of reaching efficacious drug exposures in 
humans.  
Specific Aim 1
Identifying the main driver for antibiotic efficacy is essential for designing its 
optimum dosing schedules. In Specific Aim 1 (Chapter 3), I hypothesize that the ???????
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anti-mycobacterial activity of Lee 1810 follows a defined dose-exposure-response 
relationship. In order to prove this hypothesis and characterize the dose-exposure and 
exposure-response relationships for Lee 1810, I will develop a semi-mechanistic PK/PD 
modeling approach and apply it on concentration and efficacy data obtained from a dose 
fractionation study in a mouse model of chronic ??? infection.
Specific Aim 2
Spectinamides are highly water soluble and poorly permeable resulting in limited 
oral bioavailability; hence are usually administered through the subcutaneous route in 
mice. Since lungs are the main site of infection in pulmonary TB, the efficacy of lead 
spectinamide Lee 1599 was also evaluated after intratracheal administration in a mouse 
model of ??? infection. Intratracheal administration of lead spectinamide Lee 1599 was 
shown to be significantly more efficacious than subcutaneous administration at 
comparable doses. In Specific Aim 2 (Chapter 4), I hypothesize that this higher efficacy 
is caused by a higher exposure of Lee 1599 to the target organ, the lungs, after 
intratracheal compared to subcutaneous administration. I address this hypothesis in a 
comparative biodistribution assessment of Lee 1599 after subcutaneous and intratracheal 
administration in mice.
Specific Aim 3
The translation from the preclinical stage to the clinical stage is one of the most 
critical steps in a drug development program as it requires extrapolation of results for 
efficacy, safety, PK/PD and toxicology from preclinical species to humans. 
Physiologically-based pharmacokinetic (PBPK) modeling and simulation is one of the 
powerful methodologies which is increasingly used for predicting drug exposure in 
humans based on the pharmacokinetic behavior observed in preclinical species. In 
Specific Aim 3 (Chapter 5), I hypothesize that systemic exposures to Lee 1599 found to 
be efficacious in mice are also feasible to be reached in humans. I address this hypothesis 
by developing and applying a PBPK model for Lee 1599 to predict pharmacokinetics and 
dose requirements of Lee 1599 in humans. This includes the development of a PBPK 
model for describing the pharmacokinetics of Lee 1599 in rats and mice, and the 
subsequent use of the model for prediction of human pharmacokinetics of lead 
spectinamide Lee 1599. 
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CHAPTER 3.   ?DOSE-EXPOSURE-RESPONSE ANALYSIS OF
SPECTINAMIDE ANTIBIOTIC LEE 1810 IN ??????????????
???????????? INFECTED MICE
Introduction
Tuberculosis (TB) is a serious life-threatening disease resulting in 1.4 million 
deaths per year [49]. Multidrug-resistant (MDR) TB (resistant to the first line agents 
rifampin and isoniazid) causes an estimated 300,000 deaths per year [50]. To make 
matters worse, extensively drug-resistant (XDR) TB (resistant to first line agents and at 
least one second line agent) and totally drug-resistant TB (resistant to all first and second 
line agents) infections are increasing at an alarming rate in the developing world. To 
address the increasing prevalence of MDR and XDR infections, several novel scaffolds 
of antibiotics are currently being investigated in various stages of pre-clinical and clinical 
development [51]. 
Our research group has recently discovered novel antitubercular agents known as 
spectinamides. Spectinamides are semi-synthetic derivatives of spectinomycin, an 
aminocyclitol that inhibits bacterial protein synthesis by binding to a site within the 
bacterial 30S ribosome (helix 34 of 16SrRNA) distinct from that of other protein 
synthesis inhibitors. This property provides the necessary selectivity, narrow spectrum 
antitubercular activity and lack of cross-resistance with other antibiotics. In multiple 
murine infection models, spectinamides were successful in significantly reducing lung 
mycobacterial burden and also improving survival. Unlike aminoglycosides, 
spectinamides do not inhibit human mitochondrial translation and do not exhibit off-
target effects which are linked to aminoglycosides-related ototoxicity [52].  
Based upon ???????? screening assays, pharmacokinetic studies, and preliminary ???
???? efficacy studies in rodents, Lee 1810 emerged as one of the lead candidate molecules 
from the class of synthesized spectinamide compounds. Lee 1810 has a minimum 
inhibitory c??????????????????????????????? [53], a favorable pharmacokinetic profile 
with high microsomal metabolic stability and renal excretion as the primary elimination 
pathway. In mouse models of chronic ?????????????????????????? (???) infection, Lee 
1810 monotherapy reduced the lung bacterial load comparable to streptomycin. 
Given the long cycle time involved in new drug development coupled with the 
limited pipeline of antitubercular agents under development, it is essential to use novel 
antibiotics for this indication in the most appropriate way. To maximize efficacy, and 
minimize toxicity and emergence of resistance associated with spectinamides, it is critical 
to use optimum dosing strategies which are based upon pharmacokinetic 
/pharmacodynamic (PK/PD) principles. The main objective of the work summarized in 
this chapter is to develop a semi-mechanistic PK/PD model to characterize the dose-
exposure-response of lead spectinamide Lee 1810 based on a dose-fractionation study in 
a mouse model of chronic ??? infection. The PK/PD relationship established in this 
model will further support dose selection in preclinical development and will eventually 
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facilitate translation of preclinical information to humans by informing clinical trial 
designs and determining clinically optimum dosing regimens.
Materials and Methods
Chemicals and reagents 
Spectinamide antibiotic Lee 1810 (2-(5-hydroxypyridin-2-yl)-N-
((2R,4R,4aS,5aR,6S,7S,8R,9S,9aR,10aS) -4a,7,9-trihydroxy-2-methyl-6,8-
bis(methylamino)decahydro-2H-benzo[b]pyrano[2,3-e][1,4]dioxin-4-yl)acetamide) as 
shown in Figure 3-1 was synthesized in Dr. Richard E. Lee’s Lab at St. Jude Children’s 
Research Hospital, Memphis, TN as previously described [54]. Acetonitrile, methanol, 
HPLC grade water, formic acid and nonafluoropentanoic were purchased from Fisher 
Scientific (Pittsburgh, PA). Drug free BALB/c mouse plasma was purchased from 
Innovative Research (Novi, MI).
Dose-fractionation study in a chronic mouse model of ???
6-8 week old BALB/c female mice (150 total) were infected with ??? Erdman 
with a Low Dose Aerosol (LDA) infection as previously described [49], using an 
inoculum concentration of 2.0×106 CFU/ml to achieve deposition of ~100 CFU in the 
lungs for the BALB/c mice. At Day 34 post infection, subcutaneous (SC) administration 
with Lee 1810 was initiated with different dosing regimens as described in Table 3-1 and 
continued for 4 weeks with drug holidays on weekends. The spectinamides were 
formulated in Plasma-Lyte (Baxter, Deerfield, IL) and water with different ratios for each 
group in order to maintain ideal osmotolerance close to physiological values, and 0.2 ml 
of the formulation was administered subcutaneously using a 29 gauge insulin syringe. To 
assess the pharmacokinetics of Lee 1810 under multiple dosing in infected mice, two 
blood samples were taken per mice by submandibular bleed collected in BD Microtainer 
plasma separator tubes containing lithium-heparin (BD, Franklin Lakes, NJ): one at 0.25 
h post SC administration (C0.25) and another at the 8 h post SC administration during the 
last week of dosing (C8). Plasma was separated immediately by centrifugation (10,000g 
??????? ???????????????????????????????????????????????????????????eks of treatment 
followed by 2 days of washout period, lungs were harvested and homogenized for 
dilution and plated on Middlebrook 7H11 agar plates supplemented with oleic acid-
albumin-dextrose-catalase (OADC). Plates were incubated at 37°C and colonies (CFU) 
were enumerated after at least 21 days of incubation. To enumerate the bacterial uptake 
from the LDA infection, 6 BALB/c mice were sacrificed day 1 post-infection. On Day 34 
post-infection, 5 BALB/c mice were sacrificed to determine bacterial load at the start of 
therapy. On Day 62 post-infection, 5 BALB/c untreated mice and 7 BALB/c mice dosed 
with vehicle were sacrificed to determine bacterial load in the untreated group and 
placebo group respectively. This information was used for describing the natural bacterial 
growth. The viable CFU counts were logarithmically converted for further data analysis. 
19
Figure 3-1. Structure of Lee 1810 
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Table 3-1. Dosing regimens evaluated in the dose-fractionation study
Dosing 
frequency
Total weekly dose (mg/kg)
20 40 60 80 100 120 200 300 400 500 600 1000 1200 2000 3000 4000
5x per 
week 
(m-f) 
twice
10
BID
20
BID
50
BID
100
BID
200
BID
300
BID
400
BID
5x per 
week 
(m-f)
20
QD
40
QD
100
QD
200
QD
400
QD
600
QD
3x per 
week 
(m,w,f)
20
TIW
40
TIW
100
TIW
200
TIW
400
TIW
2x per 
week 
(m,r)
20
BIW
40
BIW
100
BIW
200
BIW
1x per 
week (m)
20
QW
40
QW
100
QW
Abbreviations: m, Monday; t, Tuesday; w, Wednesday; r, Thursday; f, Friday; BID, Twice daily; QD, Once daily; TIW, Thrice 
weekly; BIW, Twice weekly; QW, Once weekly.
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The dose-fractionation study was conducted in the dedicated BSL-3 facility by the 
research group of Dr. Anne Lenaerts at Colorado State University according to the 
guidelines of the Colorado State University Institutional Animal Care and Use 
Committee. As the plasma samples were collected from ??? infected mice, it was 
nece???????????????????????????????????????????????????????????????????????-irradiation at 
a radiation dose of 1 Mrad using a Cobalt-60 gamma irradiator was used for sterilization 
of the plasma samples. To account for degradation of drug during the irradiation process, 
quality control samples of known concentrations (10 ng/mL (low), 1 μg/mL (medium), 
and 10 μg/mL (high)) were simultaneously irradiated. After sterilization, the sample 
concentrations were quantified and the concentrations were corrected for the drug lost 
during the irradiation procedure. 
Pharmacokinetic study in healthy mice
To assess the pharmacokinetics in healthy compared to infected mice and to 
provide an anchor point for a population pharmacokinetic analysis of the limited samples 
obtained in the mouse model of chronic ??? infection, female BALB/c mice (6–8 weeks 
old, ~20 g, n = 15) were dosed with 200 mg/kg of Lee 1810 subcutaneously. Blood 
samples were collected at 0.083, 0.25, 0.5, 1, 2, 3, 5, 8, 12 and 24 h after administration. 
Each mouse provided two blood samples, one by a one-time retro-orbital bleed under 
isoflurane anesthesia and the other by cardiac puncture under isoflurane anesthesia 
followed by euthanasia through cervical dislocation. This pharmacokinetic study was 
performed at the University of Tennessee Health Science Center following approval by 
the Institutional Animal Care and Use Committee. Plasma was separated immediately by 
??????????????????????????????????????????????????????????????-MS/MS analysis. 
Quantification of Lee 1810 concentrations in plasma
????????????????????????????????????????????????????????????????????????????? of 
specimens ??????? ?????????????????????????????????????????????????????-dihydro-??-
deoxy-?????-isopropylacetylamino spectinomycin) was added. This was followed by 
vortexeing for 1 min and centrifugation at 10,000g for 10 min at 4oC. The supernatant 
was ?????????????????????????????????????????????????????????-performance liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS). 
Chromatographic separations were carried out using a Shimadzu Nexera XR (LC-
20ADXR) liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) consisting of two 
pumps, online degasser, system controller and an autosampler. Liquid chromatography 
????????????????? ???????????????????????????????????? ??????????????????
Milford, MA). The mobile phase was solvent A (water with 1.6% nonafluoropentanoic 
acid and 0.7 % formic acid) and solvent B (90% acetonitrile with 0.8% 
nonafluoropentanoic acid and 0.35% formic acid) in the gradient mode as follows: 0–0.5 
min, 20% B; 0.5–1.6 min, 20–90% B; 1.6–2 min, 90% B; 2-2.5 min, 90-20% B, 2.5–3 
min, 20% B at a flow rate of 0.5 mL/min. Analytes were detected with a API 5500 triple-
quadruple mass spectrometer (Applied Biosystems, Foster City, CA) with electrospray 
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ionization in multiple reaction monitoring mode using the compound-specific mass 
transfers of m/z 469.2/ 207.1 for Lee 1810 and m/z 418.3/207.1 for Lee 1369. 
Two calibration curves ranging from 1.95 to 2,000 ng/mL and 1.95 to 1000 
μg/mL were constructed and validated with spiked samples of mouse plasma. Samples 
with concentrations above 2000 ng/mL were analyzed with the higher calibration range. 
The peak area ratios of analyte to internal standard was linear over the concentration 
range tested for both compounds, with correlation coefficients (weighted least-square 
linear regression analyses) >0.997. Accuracy (deviation of the analyzed quality control 
samples from nominal values) was within ±3% over the entire range of the calibration 
curve, and precision (coefficient of variation of repeated measurements of the quality 
control samples) was <2%.
Dose proportionality assessment
The assessment of dose linearity and dose proportionality was performed by 
power regression modeling on log-transformed data for C0.25 and C8. 95% confidence 
intervals for the slopes were determined from the power regression analysis. The dose 
??????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????[55]. 
Population pharmacokinetic model development 
A population pharmacokinetic model was used to simultaneously describe the 
plasma concentration measurements from both healthy and infected mice by nonlinear 
mixed-effects modeling. The concentration data were natural log transformed and 
modeled using a log-transform-both-sides (LTBS) approach [56]. The evaluation of the 
structural pharmacokinetic model was undertaken by visual exploratory data analysis. 
The densely sampled concentration-time points in the healthy mice were primarily used 
to guide base model development. Once the base model could adequately describe the 
data in healthy mice with physiologically plausible parameter estimates, the model was 
expanded to include the sparse pharmacokinetic data from the dose-fractionation study. 
Based upon the biphasic distribution of Lee 1810 after SC administration, a two-
compartment model with first-order absorption was used to describe the 
pharmacokinetics of Lee 1810 (Figure 3-2).
For all models evaluated in this population analysis, between-subject variability 
(BSV) was modeled as a log-normal distribution,
?? = ????  × ???        Eq. 3-1
where Pi is the parameter estimate for mouse i, Ppop represents the typical population 
value for the parameter, and ?i is the independent random variable in mouse i, described 
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Figure 3-2. Two-compartment pharmacokinetic model for characterizing the 
pharmacokinetics of Lee 1810 
Abbreviations: C, concentration in the central compartment; CP, concentration in the 
peripheral compartment; Q/F, intercompartmental clearance corrected for bioavailability; 
CL/F, clearance corrected for bioavailability; Ka, first-order absorption rate constant.
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by a normal distribution with mean zero and variance ?2, which corresponds to a log-
normal distribution for the parameter.
The residual unexplained variability (RUV) was characterized as an additive 
error, which relates to a proportional error when using an LTBS approach, such that: 
??(???) = ??? ???? + ???        Eq. 3-2
where Ln?Cij? is the natural logarithm of the jth observed concentration in the mouse i, 
Ln??ij? is the natural logarithm of the model predicted concentration for the jth
observation in the mouse i, and ?ij is the residual error characterized by normal 
distribution with mean zero and variance ?2.
Following the development of the base model, disease effect was tested as a 
categorical covariate coded as power model on clearance (CL/F), central volume of 
distribution (Vc/F) and intercompartmental clearance (Q/F) using the following 
relationship:
? = ?? × (??)??????        Eq. 3-3
where P represents the typical value of parameter in the population, Status is an indicator 
variable equal to 0 for healthy mice and 1 for infected mice, ?1 is the typical value of P 
for healthy mice, and ?2 is the multiplicative factor describing the increase or decrease in 
P as a result of the infection.
To account for the more than dose-proportional increase in C0.25 above doses of 
100 mg/kg as observed in the data, a higher absorption rate for these groups was tested 
using the following relationship: 
????? = ?? × (??)??        Eq. 3-4
where PopKa represents the typical value of Ka in the population, HD is an indicator 
?????????????????????????????????? ????????????????????????? ???????3 is the typical 
value of Ka ?????????????? ???????????4 is the multiplicative factor describing the 
increase in Ka for dose >100 mg/kg. 
Semi-mechanistic PK/PD model development
The semi-mechanistic PK/PD model developed to describe the effect of Lee 1810 
on ??? in the murine infection model takes into consideration the time course of bacterial 
count based on ??????? information. The model was composed of three basic components: 
(i) a component that describes the bacterial growth kinetics, (ii) a component that 
describes the pharmacokinetics of Lee 1810, and (iii) a component that integrates the 
effect of the drug concentration on bacterial turnover. 
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The natural bacterial growth of ??? in the control group of untreated 
immunocompetent mice was characterized based on time courses of CFU data obtained 
from this study, previously performed studies by Dr. Anne Lenaerts’ research group at 
Colorado State University using the same mouse and bacterial strains, and from the 
scientific literature (Figure 3-3) [57-59]. The growth kinetics in untreated groups of mice 
was found to be independent of the bacterial or mouse strain used in the study (Table 
3-2). This is consistent with the observations made previously where mice infected 
intravenously or aerogenically with ??? strains of CDC 1551, Erdman, H37Rv developed 
almost identical infections in the lungs and spleen [60]. 
The model for natural mycobacterial growth in the untreated group of 
immunocompetent mice was developed by implementing the idea of phenotypic 
heterogeneity, where a fast growing bacterial population (N1) switches into a slow 
growing population (N2) as a result of stochastic or induced expression of persister genes 
as shown in Figure 3-4 [61]. The implementation of this model was inspired from the 2-
subpopulation approach used for describing the ???????? growth kinetics of ??????????????
???????? [17]. In the early exponential growth phase, N1 is assumed to constitute the 
majority of total bacteria with a first-order replication rate of Krep.The conversion from 
the fast growing stage to the slow growing stage was assumed to be triggered by a high 
total bacterial population. In the model, the N2 have the ability to revert back to the fast 
growing bacteria once the conditions become favorable. However, during initial model 
evaluation, the transfer from N2 to N1 was negligible and was therefore fixed to 0 in 
further model development. The mice used in the dose-fractionation study were 
immunocompetent. Interferon-?????????????-cells, which regulate the adaptive immune 
system, are recruited to the lungs post-infection in aerosol infected mouse models [59]. In 
order to account for the role of host immune reaction in killing bacteria, a first-order 
death rate constant Kir was introduced on both bacterial subpopulations. The CFU 
readout from the agar plates was considered to represent the sum of both bacterial 
subpopulations. The initial number of bacteria in the fast growing subpopulation (N1, 0)in 
the starting inoculum was estimated during the model fit. Since the mice were challenged 
with a low-dose aerosol inoculum of bacteria in the early logarithmic phase, the initial 
number of N2 was fixed to 0. 
???
??
=  ???? × ?? ?  ??? × ?? ?  (???? ? ???) × ?
?????
????
? × ??   Eq. 3-5
???
??
= (???? ? ???) × ?
?????
????
? × ?? ?  ??? × ??    Eq. 3-6 
Once the natural bacterial growth model had been developed, the next step was to 
integrate it with the drug effect. Based on the individual ???????? estimates from the 
population pharmacokinetic modeling, a sequential PK/PD analysis was performed by 
linking the pharmacokinetic model with the bacterial growth model via an exposure-
dependent kill function associated with the effect of Lee 1810 as shown in Figure 3-5.
The parameters related to the natural bacterial growth model were fixed during the drug 
evaluation and only the drug effect parameters were estimated during the PK/PD 
analysis.
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Figure 3-3.  Natural bacterial growth of ?????????????????????????? in the 
untreated group of immunocompetent mice
Dunphy ?????? [58], Rifat ?????? [57], Tischler ?????? [59] and US Patent 7722861B2 [62] 
represents the literature sources from which the data was extracted. CSU_1 represents the 
data obtained from the current dose fractionation study of Lee1810 and CSU_2, CSU_3 
and CSU_4 are the time courses of CFU data obtained from previously performed studies 
by Dr. Anne Lenaert’s research group at Colorado State University using the same mouse 
and bacterial strains.
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Table 3-2. Information about the bacterial and mouse strain reported in the 
literature sources from which the data was extracted for the natural bacterial 
growth of ?????????????????????????? in the untreated group of immunocompetent 
mice
Literature source Bacterial strain Mouse strain
Dunphy ?????? H37Rv C57BL/6
Rifat ?????? CDC1551 BALB/c
Tischler ?????? Erdman C57BL/6
US Patent 7722861B2 H37Rv C57BL/6
CSU_1, _2, _3, _4 Erdman BALB/c
Dunphy ?????? [58], Rifat ?????? [57], Tischler ?????? [59] and US Patent 7722861B2 [62] 
represents the literature sources from which the data was extracted. CSU_1 represents the 
data obtained from the current dose fractionation study of Lee1810 and CSU_2, CSU_3 
and CSU_4 are the time courses of CFU data obtained from previously performed studies 
by Dr. Anne Lenaerts’ research group at Colorado State University using the same mouse 
and bacterial strains.
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Figure 3-4. Two-subpopulation ?????????????????????????? growth model 
Abbreviations: N1, cell count of fast growing population; N2, cell count of slow growing 
population; Krep, first-order replication rate constant; Nmax, maximum number of bacteria;
Kir, first-order death rate constant induced by the immune reaction. 
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Figure 3-5. PK/PD model of Lee 1810 consisting of a two-compartment pharmacokinetic model and ??????????????
?????????????growth model integrated with additive drug effect
Abbreviations:  N1, cell count of fast growing population; N2, cell count of slow growing population; Krep, first-order replication rate 
constant; Nmax, maximum number of bacteria; Kir, first-order death rate constant induced by the immune reaction; Emax, maximum kill 
rate induced by Lee1810; C, is concentration of Lee 1810 at time t; EC50, concentration of Lee1810 at half of Emax and ? is the 
sigmoidicity factor.
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The drug effect was evaluated as an additive effect. The additive model describes 
the drug effect as an additional kill rate as described by Equation 3-7. 
???
??
=  ???? × ?? ?  ??? × ?? ?  (???? ? ???) × ?
?????
????
? × ?? ? ?
????×??
??? ????
? ? ? ? Eq. 3-7
In the Equation 3-7 and Figure 3-4, the effect corresponds to an additional kill-rate 
constant contributed by the drug with Emax representing the maximum achievable drug-
imposed kill-rate constant having the unit 1/time and ? is the sigmoidicity factor, which 
determines the shape of the concentration-effect relationship.
The CFU data were log transformed by taking Log base 10 to Log CFU. Similar 
to the pharmacokinetic analysis, a LTBS approach was also used for the PK/PD model, 
and the unexplained residual variability was characterized using as an additive error. As a 
single sample was available per animal, it was not feasible to separately estimate BSV 
and residual variability [63]; hence only the RUV characterized as additive error was 
estimated in the model.
Model qualification
In order to comprehensively characterize the dose-exposure-response relationship 
for Lee 1810, the adequacy of the developed semi-mechanistic PK/PD model was 
evaluated by performing a Visual Predictive Check (VPC) in which the parameters 
derived from the final model were used to simulate data and compare them for their  
consistency with the observed data [64]. Monte Carlo simulation was performed with a 
total of 1000 replicates to obtain the dose-response curves ranging from weekly dose of 0 
mg/kg to 5000 mg/kg with QW, BIW, TIW, QD and BID. The primary endpoint here 
was the bacterial count at the end of drug treatment. The median value of simulations was 
plotted as a line while the 80%, 70% and 60% prediction intervals were represented as 
pink, purple and green shaded bands respectively.  
Numerical simulations for the two subpopulations
The extent of change in each of the bacterial subpopulation was simulated based 
on the final PK/PD model for all the groups tested in this study. This simulation provides 
an overview of the quantitative dynamics in bacterial population growth with different 
dosing regimens 
Data analysis and software 
The PK/PD data analysis and simulations were performed in the nonlinear mixed 
effects modeling software NONMEM (version VII, level 2.0; Icon, Hanover, MD) using 
the first-order conditional estimation (FOCE). The software suite R (version 3.2; R 
Foundation for Statistical Computing) was used for data management and graphical as 
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well as statistical assessment of models. Models were evaluated based on goodness-of-fit 
plots, objective function value, parameter precision and scientific plausibility. Model 
comparison for hierarchical models was performed using the likelihood ratio test. The 
differences in the objective function value are approximately Chi-square distributed with 
n degrees of freedom (n is the difference in the number or parameters between the full 
and the reduced model). The differences in objective function of 3.84 for 1 degree of 
freedom, corresponding to a significance level of p < 0.05, was used to discriminate two 
hierarchical models.
Results and Discussion
The overall goal of this study was to characterize the dose-exposure-response 
relationship of lead spectinamide candidate Lee 1810 in ??? infected mice using a 
PK/PD modelling approach. In order to separately tease out the impact of dose and 
dosing regimen on the response, a dose-fractionation study was conducted over a wide 
range of weekly doses, including 20-4000 mg/kg using different dosing frequencies. 
There were in total 24 dose groups with 5 mice per group (except for groups of Day 1 
post-infection with 6 mice, Day 34 post-infection with 5 mice and Day 62 post-infection 
with 7 mice). BALB/c mice were infected with a low dose aerosol of ???, followed by a 
gap of 5 weeks to allow infection to establish and subsequently treated with different 
dosing regimens of Lee 1810 as described in Table 3-1. Dosing was continued for 4 
weeks with 2 blood samples at 0.25 h and 8 h from each mice in the last week, followed 
by a washout period after which the mice were sacrificed, and the lungs removed for 
measurement of CFU. The study was successfully completed in 116 mice, resulting in 
226 concentration measurements and 116 lung CFU measurements. 4 were lost during 
the conduct of the study for non-drug related issues.
Dose proportionality  
The concentrations at 0.25 h and 8 h increased consistently with increase in dose 
as shown in Figure 3-6. For the same dose level, the concentrations at 0.25 h and 8 h 
were similar for different dosing frequencies suggesting minimal accumulation. Dose 
proportionality was evaluated by using the power regression model on the log-
transformed data for C0.25 and C8 across the dose range evaluated in the dose-
fractionation study. Plots of log-transformed C0.25 and C8 along with the regression lines 
are displayed in Figure 3-7. Results from the power regression analysis of the C0.25 and 
C8 are summarized in Table 3-3.The concentrations at C0.25 increased in a dose-
proportional fashion until 100 mg/kg, and were more than dose-proportional between 200 
– 400 mg/kg. However, concentrations at C8 were found to be dose-proportional across 
the entire dose range. The more than dose-proportional increase observed in C0.25 above 
the dose of 100 mg/kg may be caused by an increased absorption rate associated with 
faster diffusion at the subcutaneous site of administration at higher concentrations. This 
information was useful for characterizing the nonlinearity for the subsequently developed 
population pharmacokinetic model. 
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Figure 3-6. Concentration of Lee 1810 at 0.25 h (top panel) and 8 h (bottom 
panel) for the different dosing regimens evaluated in the dose-fractionation study
Each column heading represents the amount of single dose in mg/kg. The open black 
circles indicate observed data, red points indicate the mean and blue lines indicate the 
standard error of the observed data. 
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Figure 3-7. Dose proportionality assessment of C0.25 (top panel with concentration 
units in μg/mL) for a dose range of 10 - 100 mg/kg and C8 (bottom panel with 
concentration units in ng/mL) for a dose range of 10 - 400 mg/kg 
The blue line represents the regression line and red open circles represent the observed 
data.
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Table 3-3. Dose proportionality test using power regression model for Lee 1810. 
Parameter 
Dose range
(mg/kg)
Slope
95% confidence limit
Lower Upper
C0.25 10 - 400 1.19 1.10 1.27
C0.25 10 - 100 1.08 0.92 1.24
C8 10 - 400 0.918 0.792 1.04
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Population pharmacokinetic analysis of Lee 1810  
 The population pharmacokinetic modeling approach has been extensively used for 
characterizing preclinical and clinical pharmacokinetics especially in cases involving 
sparse sampling per individual/animal [65]. The non-linear mixed effects modeling 
approach was successfully applied for simultaneous modeling of the pharmacokinetics of 
Lee 1810 in healthy mice with intensive pharmacokinetic data as shown in Figure 3-8
and in infected mice with sparse sampling data. A two-compartment model with first-
order absorption and linear elimination from the central compartment was used to 
characterize the plasma concentration–time profile of Lee 1810 (Figure 3-9). The model 
was parameterized in terms of first-order absorption rate constant (Ka), clearance (CL/F), 
central volume of distribution (Vc/F), inter-compartmental clearance (Q/F) and peripheral 
volume of distribution (Vp/F). The parameter estimates along with their precision are 
given in Table 3-4. The drug undergoes rapid absorption from the subcutaneous site with 
an absorption rate constant of 2.31 h-1, which corresponds to a short absorption half-life 
of 18 min. Lee 1810 displayed a biphasic pharmacokinetic profile with its volume of 
distribution mainly limited to the extracellular fluid volume with some peripheral 
distribution. Similar to other cationic amphiphilic drugs, Lee 1810 may also have high 
binding affinity towards intracellular phospholipids, and slow release from these sites 
could be the potential reason for its prolonged terminal elimination half-life [66]. 
To account for the potentially increased absorption above the dose of 100 mg/kg, 
a separate absorption rate was included for these groups, which resulted in a significant 
drop in the objective value funct????????????- 8.99).The groups with doses above 100 
mg/kg had a mean absorption rate of 5.89 h-1 which was ~2.5-times higher than the mean 
absorption rate of 2.31 h-1 for groups with doses less than 100 mg/kg.  
Health status as a covariate on Vc/F, CL/F and Q/F improved model fits and 
???????????????????????????????????????????????????????????????????- 7.38 for Vc/F ???????
= - 7.00 for CL/F ???????????- 12.8 for Q/F). The pharmacokinetics were found to be 
different between healthy and infected mice with the later having a 56.5% lower CL/F,
69% lower Vc/F and 69.6% lower Q/F The reason for the reduced clearance is not clear, 
particularly since Lee 1810 is largely eliminated by renal excretion without major 
metabolic conversion. A 2.5- to 3-fold lower clearance, however, was also observed with 
dihydrostreptomycin in TB infected mice as compared to healthy mice [67]. In some
human patient populations, reduced clearance has also been observed for rifampin [68], 
which is typically known to exhibit increased clearance due to autoinduction during 
chronic therapy [69]. One of the potential explanations for lower CL/F in infected mice 
could be an alteration in protein binding of Lee1810. Lee 1810 is a basic drug and is 
found to have a protein binding of 40% in rat plasma. With its two ionizable basic 
mo????????????????????????????????????????????????????????????????????????????????????-
phase plasma protein that predominantly binds to basic drugs and increases in reaction to 
bacterial infections and other inflammatory stimuli [70]. For example, the plasma AAG 
concentration was found to be significantly higher in patients with plasmodium filarial 
malaria infection as compared to healthy individuals, resulting in a lower free fraction of 
antimalarial drug quinine [71]. Additionally, patients with Crohn’s disease, inflammatory 
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Figure 3-8. Concentration–time profile of Lee 1810 for a single dose of 200 mg/kg 
by subcutaneous administration in healthy BALB/c mice
The red line indicate the population prediction, black points indicate the mean and the 
blue error bars indicate the standard error of the observed data at each time point (n=3). 
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Figure 3-9. Individual Lee 1810 concentration-time profiles for the different treatment groups tested in the dose-
fractionation study
The observed concentrations (open black circles) and population predictions (thick red line) are depicted for the time period of 56 to 
60 days after initiation of infection (equivalent to 22 to 26 after initiation of dosing).
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Table 3-4. Population pharmacokinetic model parameter estimates 
Parameters
Typical value
(%RSE)
%BSV
(%RSE)
Ka (h
-1) 2.31 (17.8)
Vc/F (L/kg) 0.435 (21.6)
Vp/F (L/kg) 0.161 (22.2)
CL/F (L/h/kg) 1.17 (9.30) 19.9 (53.7)
Q/F (L/h/kg) 0.0191 (21.5)
Effect of disease on CL/F 0.435 (19.5)
Effect of disease on Vc/F 0.310 (24.2)
Effect of disease on Q/F 0.304 (29.3)
Ka > 100mg/kg 5.89 (15.8)
RUV(%CV) 49.3 (7.3)
Abbreviations: Ka, absorption rate constant; Vc/F, volume of central compartment 
corrected for bioavailability; Vp/F, volume of peripheral compartment corrected for 
bioavailability; CL/F, clearance corrected for bioavailability; Q/F, intercompartmental 
clearance corrected for bioavailability; Effect of disease on parameter was determined 
using the following relationship: P=?1×??2)
Status, where P represents the typical value of 
parameter in the population, Status is an indicator variable equal to 0 for healthy mice 
and 1 for infected mice, ?1 is the typical value of P for healthy mice, and ?2 is the 
multiplicative factor describing the increase or decrease in P as a result of the infection 
; Ka > 100 mg/kg, absorption rate constant for dose above 100 mg/kg; RUV, Residual 
Unexplained Variability
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arthritis, and chronic renal failure also had increased levels of AAG and reduced free 
fraction of basic drugs like propranolol and chlorpromazine [72]. Based on these 
observations, it is possible that TB infected mice may have elevated levels of AAG which 
reduces the free fraction of Lee 1810 and this ultimately results in reduction of its renal 
clearance. Increase in plasma protein binding of Lee 1810 could also result in reduced 
Vc/F. Reduced Vc/F of Lee 1810 in infected mice could potentially be explained by 
dehydration in infected mice which resulted in reduction in average body weight from 21 
g on Day 1 of treatment to 20.3 g on the final day of study leading to reduced volume of 
distribution. Lee1810 based on its physico-chemical characteristics is mainly limited to 
the extra-cellular space which decreases with decrease in body weight. The distribution 
of Lee1810 via the diffusion process would also be reduced by the decreased fluid 
content and this could also explain the reduction in Q/F observed in infected animals. 
Similar observations were also seen in dehydrated goats which lost on an average 10-
13% of their body weight resulting in significant changes in distribution and elimination 
parameters of oxytetracycline [73]. Further research needs to be conducted to better 
understand the reason for the differences in pharmacokinetics between healthy and 
chronically infected mice.
Effect of dosing regimen on the bacterial counts
After four weeks of therapy in mice chronically infected with ???, Lee 1810 
exhibited a dose-dependent decrease in the bacterial counts with saturation at doses above 
200 mg/kg as shown in Figure 3-10. Figure 3-11 indicates the concentration-dependent 
rather than time-dependent killing characteristics of Lee 1810 as suggested for the 
spectinamides similar to Lee 1810 [52]. For example, a weekly dose of 500 mg/kg when 
given as 100 mg/kg QD resulted in better efficacy compared to 50 mg/kg BID. Similar 
trends were also observed with dose fractionation of other weekly doses where 
intermittent dosing provided improved efficacy relative to more frequent dosing 
regimens. Drugs with concentration-dependent bacterial killing characteristics are 
associated with a dramatic reduction in bacterial count as a consequence of a rise in drug 
concentrations [74].This could potentially be explained by the ability of spectinamides to 
accumulate inside the macrophages [75] promoted by lysosomal trapping and attain high 
concentration to kill the intracellular form of ???. This intracellular accumulation would 
likely be facilitated by high concentration gradients that drive drug molecules across the 
bacterial cell wall into the intracellular compartment.
Model-based characterization of the natural growth of ??? in infected mice 
In the immunocompetent mouse chronic infection model, TB infection undergoes 
a transition from an initial exponential growth phase to a long-term stationary phase, 
where the overall growth rate diminishes markedly [76, 77]. This may be conceptualized 
as a manifestation of phenotypic variants which evolved within this isogenic population 
in response to the various physiological stresses like immune response, starvation,  
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Figure 3-10. Bacterial burden (Log CFU) in the lungs of ??????????????
???????????? infected mice for the different dosing regimens evaluated in the dose-
fractionation study
Each column represents the amount of single dose in mg/kg. Open black circles indicate 
the observed data, red points indicate the mean and blue lines indicate the standard error.
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Figure 3-11. Bacterial burden (Log CFU) in the lungs of ??????????????
???????????? infected mice for the different dosing regimens with same weekly dose 
evaluated in the dose-fractionation study
Each column heading represents the total weekly dose amount in mg/kg. Open black 
circles indicate the observed data, red points indicate the mean and blue lines indicate the 
standard error.
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acidification and hypoxia [78]. The developed two-subpopulation bacterial growth model 
adequately described this phenotypic switching from the fast growing metabolic state to  
the slow growing/non-replicating state. Figure 3-12 for the natural bacterial growth in 
the untreated group predicts that during the early phase of infection, most of the total 
microbial population consists of the fast growing subpopulation (N1) which results in 
exponential growth. Under the pressure of host immune response and other stresses, the 
system gradually shifts into the stationary phase with increasing number of bacteria in the 
slow growing subpopulation (N2), which are better equipped to sustain themselves in the 
unfavorable conditions [79]. Recently, it was also demonstrated that the slow growing 
subpopulation retains their metabolic activity [80], and also have the ability to reactivate 
growth upon detection of a favorable signal or environment [81, 82]. 
The replication rate constant for the fast growing population (Krep)was found to 
be 0.0327 h-1 (Table 3-5) and the corresponding doubling time was calculated as 21.2 h, 
which is within the range reported in the literature (13–80 h) [19, 83-86]. This slow ???
???? growth rate is a hallmark of ???, a characteristic that may contribute to its 
persistence in the host without manifestation of clinical symptoms, yet preserving the 
ability to reactivate and disseminate [87]. Since growth rate of fast growing bacteria 
when described using a logistic function did not improve the fit of the natural bacterial 
growth model, a simple first-order growth rate constant was used for describing 
replication in the fast growing bacteria. 
Model-based characterization of the dose-exposure-response relationship for Lee 
1810 in ??? infected mice
To account for the killing effect by Lee 1810 exposure, the concentration from the 
central compartment of the pharmacokinetic model was linked to the natural bacterial 
growth model. The drug effect was implemented as an additive component to the natural 
death rate of the bacteria via an Emax-type model. (Equation 3-7). A sigmoidal Emax
model resulted in a significantly improved fit as compared to an ordinary Emax model 
????????- 51.3). The Hill coefficient was substantially greater than 1, which is a typical 
characteristic that has also been observed for other antibiotics with concentration-
dependent killing (Table 3-6) like streptomycin and rifampin, which displayed a hill 
coefficient of 1.9 and 2.5 respectively. A high value of the Hill coefficient is indicative of 
a steep concentration-effect relationship [74].  
The concentration that produced the half-maximal effect EC50 (239 μg/mL) was 
found to be much higher than MIC (1.6 μg/mL) of Lee 1810. This was expected, as EC50
describes the effect on the rate constant for drug-induced bacterial killing and is much 
more realistic parameter to compare potency of compounds with regard to bacterial kill 
than the MIC. The experimentally determined MIC represents the lowest concentration at 
which no growth of microorganism is visible to the naked eye. MIC is usually estimated 
at a fixed concentration and does not resemble the physiological conditions in which the 
drug concentrations changes with time. Additionally, the inoculum size and percentage 
contribution of the bacterial sub-population also contribute to the differences between  
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Figure 3-12. Natural growth model fitted typical Log CFU-time profile for the 
untreated group data obtained from literature and CSU studies
Model predicted Log CFU in the fast growing subpopulation (N1 , blue line), slow 
growing subpopulation (N2 , green line), total population (red dash line) and observed 
Log CFU (open black circles) are depicted. 
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Table 3-5. Parameter estimates of the ?????????????????????????? natural 
growth model
Parameters
Typical value
(%RSE)
%BSV
(%RSE)
Krep (h
-1) 0.0327 (33.3) 70.8 (57.7)
N1,0 (Log CFU) 1.93 (9)
Nmax (Log CFU) 6.44 (1.2) 54.7 (58.5)
Kir(h
-1) 0.00303 (3.6)
RUV (% CV) 32.4 (19.6)
Abbreviations:N1,0, cell count of fast growing population at the initiation of the infection; 
Krep, first-order replication rate constant; Nmax, maximum number of bacteria; Kir, first-
order death rate constant induced by the immune reaction; BSV, Between Subject 
Variability; RUV, Residual Unexplained Variability.
45
Table 3-6. Parameter estimates of the final PK/PD model of Lee 1810 
Parameters
Typical value
(%RSE)
EC50 (μg/mL) 239 (0.167)
Emax (h
-1) 11.9 (0.485)
 ? 2.40 (0.142)
RUV (% CV) 20.6 (4.2)
Abbreviations:Emax, maximum kill rate induced by Lee1810; EC50, concentration of Lee
1810 at half of Emax; ?, Hill function.
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EC50 and MIC [88]. MIC also assumes an all-or-nothing effect on the bacterial growth. In 
contrast, EC50 captures the drug’s effect on the rate of bacterial killing. Bacterial killing 
is already achieved at concentrations much lower than EC50, but at a much lower 
magnitude than at concentrations above EC50. The effect achieved at EC50 is half of the 
maximum kill rate constant achievable with Lee 1810.
The RUV in the PK/PD model was described using an additive error model. The 
modeled profiles of bacterial count versus time for all the groups as well as 
experimentally determined CFU counts are shown in Figure 3-13. The figure indicates 
that the population predictions of the PK/PD model were in close agreement with the 
observed values. 
A VPC was furthermore performed to qualify the established model. The VPC 
shown in the Figure 3-14 highlights the ability of the model to reasonably predict the 
central tendency and the variation in the bacterial count. The impact of dosing frequency 
on efficacy of Lee 1810 was also captured by the VPC where the rate of reduction in the 
bacterial load with increasing doses was steeper with decrease in dosing frequency. 
Alternative models and model limitations
Alternative PK/PD models could not fit the data as well. A natural bacterial 
growth model with single population could describe the untreated group data equally well 
as the two-subpopulation model; however it was not able to describe the dose-exposure- 
response for all the different dosing regimens as a higher bacterial kill was predicted for 
groups with more frequent dosing as compared to the ones with intermittent dosing. The 
addition of drug effect was also tested on the slow growing population but it resulted in 
over-parameterization with no convergence and poor fits. 
The presented model has several limitations. Firstly, the PK/PD model was based 
on the total bacterial count and no measurements were made to separately identify the 
percentage of each subpopulation in the two-subpopulation modeling approach. 
Quantification of each subpopulation could be helpful in distinguishing competing 
models which can describe the data equally well. Secondly, the model has not been 
studied for different bacterial strains, inoculum size, and immune status in different 
preclinical models. For example, the initial inoculum when taken from a stationary-phase 
culture will most likely have a higher proportion of slow growing bacteria as compared to 
an inoculum from a log-phase culture, which could eventually have an impact on the 
entire time course of relative bacterial dynamics. The mycobacterial populations in 
immunodeficient strains of mice (e.g., IFN-?-knockout mice) have reduced phenotypic 
heterogeneity, and higher growth potential as compared to the immunocompetent mouse 
model used in this study [80]. In these situations, appropriate modification in the natural 
growth model will be required to describe the bacterial kinetics. Thirdly, there are 
differences in the pathophysiology and disease progression of ??? between mice and 
humans. The mouse model used in this study develops granulomas that consist of loose  
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Figure 3-13. Individual Lee 1810 Log CFU-time profiles for the different treatment 
groups evaluated in the dose-fractionation study
The observed Log CFU (open black circles) and population predictions (thick red line) 
are depicted. The black dash line indicates the time when treatment was initiated.
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Figure 3-14. Visual predictive check (VPC) of the PK/PD model for the describing 
the weekly dose-response relationship
Top Panel: Weekly dose range from 0 to 1000 mg/kg. Bottom Panel: Weekly dose range 
from 0 to 5000 mg/kg. Pink, purple and green bands represent 80% prediction interval, 
70% prediction interval and 60% prediction interval of simulated data respectively. The 
solid black line is the median of simulated data and open circles are the observations.
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aggregates of lymphocytes and macrophages which do not progress into the well-formed 
necrotic granulomas observed in humans [89]. The drug exposure in plasma may not 
equilibrate homogeneously within the granulomatous lesions, and this could potentially 
complicate the translation of exposure-response relationship from mice to humans. 
PK/PD modeling results in perspective with antitubercular combination therapy
The developed PK/PD model was applied to simulate the relative dynamics of fast 
growing and slow growing subpopulations as conceptualized in our modeling approach. 
The simulations presented for different dosing regimens in Figure 3-15 suggests that 
weekly doses ranging from 100 mg/kg for twice weekly dosing down to 50 mg/kg for 
twice daily dosing is sufficient to kill most of the fast growing bacteria and further 
increases in dose may only result in marginal increases in efficacy. Based on these 
simulations, it can be speculated that further enhancement in efficacy and shortening of 
treatment duration could be achieved by combining spectinamides with other anti-
tuberculosis agents which are active against the slow growing population including 
pyrazinamide (PZA) and rifampin. PZA, a first line anti-tuberculosis therapy has unique 
pharmacological activity as it is less effective against the fast growing tubercle bacilli but 
more effective against the slow growing/non-replicating bacteria [90]. Pyrazinoic acid, 
which is the active moiety of pyrazinamide, acts by disrupting the membrane energetics 
and inhibiting the membrane transport function preferentially against the non-replicating 
bacilli which are associated with low membrane potential and acidic pH [91]. This could 
be one of the potential explanations for the significantly improved efficacy observed in a 
recently conducted combination trial of Lee 1599 (structural analog of Lee1810 and a 
competing lead spectinamide candidate) along with PZA in a high dose aerosol mice 
infection model that was performed by Dr. Anne Lenaert’s research group at Colorado 
State University (Figure 3-16). Lee 1599 was found to be as efficacious as Lee 1810, 
whereas PZA had modest activity as a single agent. The combination of Lee 1599 and 
PZA resulted in a significant reduction in bacterial count compared to the same drugs 
when used alone. This synergistic effect in combination could possibly be the outcome of 
each drug’s ability to act on a different subpopulation of bacteria. 
Looking ahead, this PK/PD model could also be used for simulating untested 
scenarios and for quantitative comparison of different dosing strategies as well as 
competing lead candidates. Furthermore, the PK/PD relationship established with this 
model could be integrated with the information about antibiotic susceptibility, drug 
associated adverse effects, and pharmacokinetics in different patient populations to 
perform simulations for identifying clinically optimum dosing regimens and also help in 
informing clinical trial designs. This semi-mechanistic model-based approach also 
provides a framework for evaluating the dose-exposure-response analysis of other 
investigational anti-tuberculosis agents. The differentiation of drug-specific and 
mycobacterium specific parameters makes it convenient to apply this model for scenarios 
other than those reported for this drug and study. 
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Figure 3-15. PK/PD model predicted Log CFU in the fast growing state, slow 
growing state and total population for the different treatment groups evaluated in 
the dose-fractionation study
Model predicted Log CFU in the fast growing subpopulation (N1, blue line), slow 
growing subpopulation (N2, green line) and total population (red dash line) are depicted. 
The black dash line indicates the time when treatment was initiated.
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Figure 3-16. ??????? efficacy trial showing bacterial burden in the lungs for combination of spectinamides with pyrazinamide 
in a BALB/c mouse (n=3-6) infection model following high dose aerosol infection of ?????????????????????????? Erdman (mean 
± s.e.m.) 
Lee 1599 /Lee 1810 were subcutaneously dosed at 200 mg/kg and pyrazinamide (PZA) was orally dosed at 150 mg/kg. All treatments 
were given QD, 5 days a week for 4 weeks.  
Fast growing
Slow growing
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In summary, the efficacy of Lee 1810 was largely driven by concentration-
dependent killing, and this supports the use of intermittent dosing. A two-subpopulation  
bacterial growth model adequately described the phenotypic heterogeneity associated 
with ??? infection in immunocompetent mice. This model component was integrated 
with the pharmacokinetics of Lee 1810 to successfully describe its dose-exposure-
response relationship. The semi-mechanistic PK/PD modelling approach allowed for a 
more comprehensive characterization of drug efficacy as compared to the MIC based 
PK/PD index approach. Based on the PK/PD model it was hypothesized that improved 
efficacy could be achieved by combining spectinamides with sterilizing anti-tuberculosis 
agents. This hypothesis was supported by the synergistic activity obtained with 
combination of Lee 1599 and PZA. Preclinical PK/PD assessments of Lee1810 will be 
useful for determining it’s preclinically and clinically optimum dosing regimen. This 
semi-mechanistic model-based approach also provides a framework for investigating the 
PK/PD relationship of other investigational anti-tuberculosis agents.
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CHAPTER 4.   ?COMPARATIVE PHARMACOKINETICS OF SPECTINAMIDE 
ANTIBIOTIC LEE 1599 AFTER INTRATRACHEAL AND SUBCUTANEOUS 
ADMINISTRATION FOR THE TREATMENT OF TUBERCULOSIS 
Introduction
Spectinamides are a novel semisynthetic series of spectinomycin analogs with 
excellent narrow-spectrum antitubercular activity. They exhibit selective ribosomal 
inhibition and are not cross-resistant with the existing tuberculosis therapeutics. 
Spectinamides maintain activity against Multidrug-resistant (MDR) and extensively drug-
resistant (XDR) tuberculosis. Physico-chemically, spectinamides are hydrophilic in 
nature making them highly water soluble and exhibit low plasma protein binding. 
However, these analogs have poor permeability across the intestinal barrier, limiting their 
bioavailability and thus oral use. Consequently, a parenteral route such as subcutaneous 
(SC) injection was selected for dosing in efficacy studies. The lead spectinamide Lee 
1599 upon SC administration in a mouse model of ?????????????????????????? (???)
infection at a dose of 200 mg/kg QD (5 days a week) for 28 days resulted in 1.57 Log 
CFU (colony forming unit) reduction in the lungs. This excellent anti-mycobacterial 
activity of Lee 1599 was similar to streptomycin at similar doses in the lungs [52]. 
Historically, orally and parenterally administered antibiotics have been used to 
treat patients with lung infections, but the downside is that they do not directly target the 
lungs [92]. Therefore in order to deliver even moderate concentrations of antibiotic to the 
lungs, the primary site of infection, the required overall systemic exposure is usually high 
and thus increases the potential for the emergence of side effects [93, 94]. The delivery of 
antibiotics via the inhalation route potentially leads to much higher concentrations of 
antibiotic in the lungs. It also increases the possibility of targeting alveolar macrophages 
which may allow the delivery of drugs to the intracellular (phagosomal) compartment. 
Additionally, inhaled therapies have the potential to stimulate innate bactericidal 
?????????????????????????????????????????????? ???????????????[95]. The development of 
resistance during antimicrobial therapy stems at least partially from the fact that when 
administered systemically many antimicrobial drugs fail to reach therapeutically effective 
concentrations in the lungs or penetrate into the alveolar macrophages, a reservoir for 
intracellular infections [96, 97]. High local concentrations are consequently needed to 
prevent amplification of less sensitive pathogens, especially when located intracellularly 
[98]. Intrapulmonary administration can deliver high concentrations of drug to the lung 
tissue and macrophage cytosol, po????????????????????????????????????????????????
resistance [97, 98]. 
Inhalational delivery has revolutionized the treatment of chronic ????????????
?????????? infections in cystic fibrosis (CF) since the FDA approval of TOBI 
(tobramycin inhalation solution) in 1997 followed by CAYSTON (aztreonam for 
inhalation solution) in 2010. In Europe, a third antibiotic from the polymyxin family is 
approved in CF, colistimethate sodium, a prodrug of colistin, but it is not approved in the 
United States [94]. Use of inhaled antibiotics in CF has been shown to decrease 
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?????????????????????? colonization, delay onset of chronic infection, increase lung 
function, improve the quality of life, and correlates with a reduction in morbidity, the 
number of exacerbations and the number of hospital admissions when compared to 
systemic administration [94]. 
Based on the experiences described above, the efficacy of Lee 1599 had been 
evaluated after intratracheal (IT) administration in the same mouse model of ???
infection as used in our previous studies [99]. A dose of 200 mg/kg TIW (3 days a week; 
Monday, Wednesdays and Fridays) for 28 days demonstrated excellent efficacy with a 
2.2 Log CFU reduction in the lungs. This antitubercular activity was comparable to that 
of rifampin (administered orally at 10 mg/kg, 5 days per week) [52].  
It was hypothesized that the excellent efficacy following intrapulmonary delivery 
of Lee 1599 may be a result of extensive distribution of the free drug within the lungs. In 
this chapter, we test this hypothesis by performing a comparative tissue distribution study 
of Lee 1599 in BALB/c mice following SC and IT administration. In addition to the 
lungs, distribution in other organs such as spleen, liver and kidneys were also evaluated 
to better understand the impact of tissue distribution on overall efficacy of Lee 1599. 
Material and Methods 
Animal study
Healthy female BALB/c mice (n= 15) were administered a dose of 200 mg/kg of 
Lee 1599.2HCl by IT aerosol delivery with a PennCentury MicroSprayer PennCentury 
Inc. (Wyndmoor, PA) as previously described [99]. The tip of the device was inserted up 
???????????????????????????????????????????????????????????????????????????????????????????
nose and throat and making it easier to precisely control the delivered dose. This is in 
contrast to metered-dose inhalers and dry powder inhalers and/or nebulizers in animal 
??????????????????????????????????????????????????????????????????????????????-subject 
variability and are not capable of targeting a desired, predetermined area of the lungs. At 
pre-dose and 0.25, 1, 3, and 8 h after administration, mice (n=3) were sacrificed 
humanely. Lungs, spleen, liver, and kidneys were immediately harvested and frozen in 
liquid nitrogen. Blood obtained by cardiac puncture was collected in heparinized 
collection tubes, and plasma was separated immediately by centrifugation (10,000 g for 
10 min at 4°C). All the plasma and tissue samples were stored at -70°C until analysis.
For comparison of plasma pharmacokinetics of Lee 1599, healthy BALB/c female 
mice (n=15) were dosed via the SC route at 200 mg/kg of Lee 1599.2HCl. Blood and 
tissue samples were collected and processed as described for IT administration. 
All animal experiments were conducted in accordance with the Animal Welfare 
Act and the Public Health Service Policy on Humane Care and Use of Laboratory 
Animals. The study protocols were approved by the Institutional Animal Care and Use 
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Committees of Colorado State University and the University of Tennessee Health 
Science Center, respectively.
Bioanalysis 
Concentrations of Lee 1599 in plasma and tissues were determined by a validated 
liquid chromatography tandem mass spectrometry assay. The frozen tissues were thawed 
at room temperature and weighed. For every 1 g of tissue 4 mL of water was added for 
homogenization using an Ultra Turrax homogenizer (IKA, Wilmington, NC). To prevent 
cross contamination between two samples, the plunger of the homogenizer was washed 
with methanol and water after each sample. Samples were further prepared by protein 
precipitatio??????? ?????????????????????????????????????????????-dihydro-??-deoxy-?????-
isopropylacetylamino spectinomycin) followed by centrifugation at 10,000 g for 10 min 
?????????????????????????????????????????????????????????????????????????????????????
hydrophobic interaction liquid chromatography (HILIC) 100 × 4.6 mm column 
(Phenomenex, Torrance, CA) using a gradient mobile phase of methanol and 10 mM 
ammonium formate, pH 2.75, at a flow rate of 0.4 mL/min. Detection was performed 
with an API 4500 triple-quadruple mass spectrometer (ABI-Sciex, Foster City, CA) with 
electrospray ionization in multiple reaction monitoring mode using the mass transfers of 
m/z 487.2/207.1 for Lee 1599 and m/z 418.3/207.1 for the internal standard (Lee 1369). 
Calibration curves were constructed for each test compound and validated with spiked 
samples of mouse plasma or respective homogenized tissue. 
Pharmacokinetic analysis
Pharmacokinetic profiles of Lee 1599 were analyzed by standard non-
compartmental procedures using Phoenix WinNonlin 6.3 (Pharsight Corporation, 
Mountain View, CA) in plasma and tissues. Penetration of drug in tissues was estimated 
from the ratios of the area under the concentration-time curve from time 0 to infinity 
(AUC0–?) for tissues compared to the AUC0–??in plasma. Total plasma clearance was 
calculated as ratio of dose and resulting plasma AUC0–?. 
Results and Discussion
After IT and SC administration Lee 1599 demonstrated very rapid absorption into 
plasma (Figure 4-1). The maximum plasma concentration Cmax was two times higher 
after IT than SC administration (Table 4-1 and Table 4-2). This is in line with the fact 
that the lungs are well known to be naturally permeable to small molecule drugs [100]. 
Although the mechanism of absorption of molecules after pulmonary deposition is still 
being researched, it seems that the lung’s tremendous surface area, very low surface fluid 
volume, thin diffusion layer and paracellular transport are some of the factors which 
contribute towards the rapid absorption of Lee 1599 into the systemic circulation. For  
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Figure 4-1. Measured concentration-time profiles (mean ± s.e.m) in different 
tissues/plasma relative to the minimum inhibitory concentration (MIC) after 
intratracheal (IT) (Left Panel) and subcutaneous (SC) administration (Right Panel)
of Lee 1599 in mice at a dose of 200 mg/kg (n=3 at each time point) 
Intratracheal Subcutaneous
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Table 4-1. Penetration ratios after intratracheal (IT) administration of Lee 1599 
in mice at a dose of 200 mg/kg 
Sample *AUC0-8h ^Cmax
#Penetration
ratio
Plasma 284 406 1
Lung 695 805 2.45
Spleen 9.36 12.9 0.0330
Liver 65 63.4 0.229
Kidney 95.9 117 0.338
Abbreviations: AUC0-8h: Area under the curve from time zero to 8 h; Cmax, Peak 
concentration. 
*AUC units for plasma (h.???????????????????????????????
^ Cmax units for p????????????????????????????????????
# ?????????? ????? =
?????????
?????????
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Table 4-2. Penetration ratios after subcutaneous (SC) administration of Lee 1599 
in mice at a dose of 200 mg/kg 
Sample *AUC0-8h ^Cmax
#Penetration
ratio
Plasma 149 192 1
Lung 21.8 9.31 0.146
Spleen 17 4.31 0.114
Liver 84.1 15.2 0.564
Kidney 191 38.7 1.28
Abbreviations; AUC0-8h: Area under the curve from time zero to 8 h; Cmax, Peak 
concentration. 
*AUC units for plasma (h.???????????????????????????????
^ Cmax ???????????????????????????????????????????????
# ?????????? ????? =
?????????
?????????
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small molecule drugs which are not dissolution rate-limited, including Lee 1599, the 
intrinsic absorption rates across the lungs are usually fast with absorption half-????????????
h, and are independent of lipophilicity or involvement of transporters [101]. The 
absorption rate also varies within the respiratory track between the epithelial cells and 
alveolar cells. There is experimental evidence that absorption of small molecules through 
the peripheral region is twice as fast compared to the central region of the lungs [102]. In 
this pilot study for Lee 1599, the disposition pattern of the formulation in the lungs was 
not evaluated. However, the rapid pulmonary absorption rate of Lee 1599 suggests that 
the drug is being delivered to the peripheral region of the lungs. This is desirable as ???
usually resides in the deeper regions of the lungs [103]. 
The systemic relative bioavailability after IT versus SC administration was 
1.91(Table 4-3). This suggests that the drug is permeable across the lung barrier to a 
larger extent compared to absorption from the SC route. The high systemic plasma 
exposure of Lee 1599 after IT administration (Figure 4-2) also suggests that close to the 
total inhaled dose was actually deposited in the lungs and that there was negligible first-
pass metabolism. Most of the small molecule drugs currently used for inhalation, 
including bronchodilators and tobramycin, are not dissolution rate-limited, and have 
approximately 100% bioavailability for the fraction of the dose deposited in the lungs 
irrespective of their permeability characteristics [101]. The relatively lower 
bioavailability after SC administration has also been observed with other aminocyclitol 
antibiotics like trospectinomycin which was 75% bioavailable in rats following SC 
administration [104]. This could potentially be explained by the incomplete and slow 
absorption from the subcutaneous site of administration. Similar to IV administration, the 
high clearance of Lee 1599 predominantly through renal excretion limits the systemic 
exposure to a relatively short duration [52].  
Information about tissue distribution is very important for the evaluation of 
efficacy and potential toxicity. As expected, the highest exposure of Lee 1599 after IT 
administration was attained in the lungs which was 2.5 times higher than plasma (Figure 
4-2 and Table 4-1). This is highly desirable as the lungs are the main site of infection in 
pulmonary TB. Dibasic compounds such as Lee 1599 usually have longer lung retention 
as compared to neutral and cationic compounds, which may be explained by the 
phenomenon of ‘lysosomal trapping’ where the basic drug accumulates in the acidic 
environment of lysosomes, which acts as a reservoir [105]. Additionally, spectinamides 
also have the ability to penetrate inside the macrophage, which is one of the main sites 
for intracellular survival and replication of ??? [75]. Macrophage uptake of spectinamide 
Lee 1329 was found to be significantly higher than spectinomycin, the parent compound 
of Lee 1329, and streptomycin, a second line anti-tuberculosis agent [75]. 
Inhalation delivery allows easier accessibility of Lee 1599 to alveolar 
macrophages, which are the predominant form of infected cells in TB, thereby creating 
high localized concentrations of the drug that can kill the intracellular ??? [89]. The 
circulation of alveolar macrophages also promotes drug distribution into the poorly-
ventilated areas of the lungs which are often a safe-haven for ??? [106]. Experimental 
evidence from rat studies involving IT administration of soluble compounds indicates  
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Table 4-3. Pharmacokinetic parameters for plasma concentration-time profiles 
after subcutaneous (SC) and intratracheal (IT) administration of Lee 1599 in mice 
at a dose of 200 mg/kg 
Route
Dose AUC0-8h CL/F t1/2 F
(mg/kg) (h.?????? (L/h/kg) (h) (Relative to SC)
IT 200 284 0.704 0.785 1.91
SC 200 149 1.38 0.847 1
Abbreviations; AUC0-8h: Area under the curve from time zero to 8 h; CL/F, Total body 
clearance corrected for bioavailability, t ½, Half-life; F, Bioavailability.
61
Figure 4-2. Measured concentration-time profiles (mean ± s.e.m) in different 
tissues relative to the minimum inhibitory concentration (MIC) after intratracheal 
(IT) and subcutaneous (SC) administration at a dose of 200 mg/kg of Lee 1599 in 
mice (n=3 at each time point)
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that t1/2 observed in lungs often mimics the apparent t1/2 observed in plasma [100]. This is 
consistent with the observations in our study. 
Although Lee 1599 is getting rapidly cleared from the lungs and plasma, excellent 
efficacy was still observed by thrice a week IT administration in mice. The potential 
explanation could be its concentration-dependent killing pattern and lengthy post-
antibiotic effect (PAE) of 133 h at 10×MIC [52]. The concentration of a drug is one of 
the major determinants of PAE. For example, the PAE of penicillin G gradually increases 
with increase in its concentration [107, 108]. In case of Lee 1599, higher concentrations 
achieved in the plasma and lungs after IT administration could potentially be associated 
with longer PAE as compared to SC administration. 
Following IT administration, Lee 1599 distributes to a similar extent in the 
kidneys and liver with penetration ratios of 0.338 and 0.229 respectively (Figure 4-2), 
although the Cmax in the liver was approximately half that in the kidneys. Passive 
diffusion across the cell membrane is highly unlikely for Lee 1599 as it is very polar 
(cLog P = -2.5) and based on its pKa of 8 and 10, it is expected to be largely in ionized 
form at physiological pH. This strongly suggests an active role of transporters involved in 
the uptake into kidneys and liver. The Biopharmaceutics Drug Disposition Classification 
System (BDDCS) classifies compounds into four types based on the solubility and 
permeability and is useful for predicting the role of transporters in the disposition of 
novel entities during the early stages of drug discovery. As Lee 1599 exhibits high 
solubility and poor permeability, it can be categorized as BDDCS Class 3 compound. 
BDDCS predicts that for class 3 drugs uptake transporters will be important for its entry 
into the liver [109]. The endocytic receptor complex formed by megalin and cubulin is 
known to transport aminoglycosides into the renal tubular epithelial cells [110]. Megalin 
associated uptake transport has also been associated with accumulation of colistin in the 
kidneys [111]. Similar to the kidneys, accumulation in the liver may also be assisted by 
hepatic uptake transporters. The highest tissue levels of trospectinomycin were found in 
the liver [112]. The mechanism behind selective hepatic sequestration was not clear; 
however it is likely that hepatic uptake transporter may be associated with it.
The lowest penetration ratio was observed in the spleen with both SC and IT 
administration indicating that Lee 1599 may not be successful in treating TB infections 
that have disseminated into the spleen (Figure 4-2). This was supported by the relatively 
lower reduction in bacterial load in the spleen as compared to the lungs observed after IT 
and SC administration of Lee 1599 [52]. This limitation, however, can likely be 
addressed by using Lee 1599 in combination therapy with other antitubercular agents 
which have better penetration and efficacy in the spleen.
In the present study, tissue penetration was found to be higher in the kidneys and 
liver, whereas it was lower in the lungs and spleens. In a previously conducted mass 
balance study of Lee1329, a structurally similar spectinamides analogue, in rats after IV 
administration [75], similar drug distribution pattern was observed with highest tissue 
penetration in the kidneys followed by liver while lower and similar penetration in lungs 
and spleen. 
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Conclusions
IT administration of Lee 1599 provides higher exposure in the lungs compared to 
the SC route. As the lungs are the main site of infection, this could potentially explain the 
improvement in efficacy with a lower weekly dose followed by IT administration. In 
spite of being highly hydrophilic, Lee 1599 accumulates in kidney and liver suggesting a 
potential role of uptake transporters in these organs. Spleen had the lowest exposure 
among all the tissues investigated following IT and SC administration. Overall, these 
results are encouraging to further pursue pulmonary delivery as an administration route 
for spectinamides in the treatment of tuberculosis.
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CHAPTER 5.   ?PHYSIOLOGICAL MODEL-BASED PREDICTION OF THE 
HUMAN PHARMACOKINETICS OF LEE 1599, A NOVEL ANTI-
TUBERCULOSIS AGENT
Introduction
The translation from the preclinical stage to the clinic is one of the most critical 
steps in drug development with an average attrition rate of 30% [113]. Successful human 
pharmacokinetic prediction based on preclinical data can be highly beneficial for any 
drug development program for calculating the first-in-human dose. One of the most 
common approaches used for prediction of human pharmacokinetics is allometric scaling, 
which typically uses body size based on a power law function to extrapolate clearance 
and volume of distribution from preclinical species to humans [114]. Allometric scaling 
adjusted for maximum lifespan potential and brain weight have also been suggested in 
order to improve its predictive capability [115]. 
Physiologically based pharmacokinetic (PBPK) modeling is an alternative 
approach which combines species-specific physiological features along with drug-
specific ?????????/???????? input parameters for prediction of pharmacokinetics in a species 
[28, 116]. Its mechanistic and more realistic modeling approach compared to empirical 
compartmental models has led to its wide spread use for studying the disposition of 
xenobiotics. Because of their intricacy, PBPK models are able to achieve a detailed 
quantitative assessment of the plasma and tissue disposition of drugs along with ease of 
scaling up the model to different species since the structural model is relatively common 
to most mammalian species and only needs size and blood flow related species-specific 
adjustments [117]. This approach in combination with physiological scaling factors has 
been successfully used for cross-species extrapolation of drugs like cyclosporine and 
docetaxel [118, 119], and in combination with pharmacodynamic data, it can also help to 
guide optimized clinical dosing. These models can also be used for predicting the 
pharmacokinetics of drugs in complex scenarios which arise as a result of multivariate 
changes to intrinsic (e.g., disease states, age, pharmacogenomics) and extrinsic (e.g., 
drug-drug interaction) factors.
Lee 1599 has emerged as one of the potential lead spectinamide candidates based 
upon its excellent microbiological, safety and efficacy profile for treatment of 
tuberculosis. It binds to a site within the mycobacterial 30S ribosome and inhibits its 
protein synthesis with a minimum inhibitory concentration (MIC) of 0.8 ????? [53]. It 
evades the efflux pump Rv1258c upregulated in drug resistant bacteria, thereby gaining 
significant efficacy in both ???????? and ??????? models of tuberculosis infection. Unlike 
aminoglycosides, Lee 1599 does not inhibit human mitochondrial translation which is 
linked to ototoxicity. In this present study, we present an application of PBPK modelling 
and simulation to predict human pharmacokinetics of Lee 1599 which was conducted in 
the following steps: 
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1. Develop and optimize a PBPK model that can describe the pharmacokinetics of 
Lee 1599 in rats after intravenous (IV) administration,
2. Prospectively qualify the performance of the model by predicting the 
pharmacokinetics of Lee 1599 in mouse after subcutaneous (SC) administration, 
and  
3. Extrapolate the PBPK model to predict pharmacokinetics of Lee 1599 in human 
after IV administration.
Materials and Methods
Chemicals and reagents
Spectinamide antibiotic Lee 1599 (3’-Dihydro-3’-deoxy-3’(R)- (5-chloropyridin-
2-yl)acetylamino spectinomycin), as shown in Figure 5-1 was synthesized in Dr. Richard
E. Lee’s Lab at St. Jude Children’s Research Hospital, Memphis, TN. Acetonitrile, 
methanol, HPLC grade water, formic acid and nonafluoropentanoic acid were purchased 
from Fisher Scientific (Pittsburgh, PA). Drug free BALB/c mouse plasma and rat plasma 
was purchased from Innovative Research (Novi, MI).  
Protein binding
The plasma protein binding of Lee 1599 in different species was determined using 
equilibrium dialysis method with ready-to-use RED device inserts (Thermo Scientific, 
Rockford, IL) in base plates containing plasma and a buffer chamber for analysis. Two 
concentrations (0.5 and 5 mg/L) of Lee 1599 were prepared in rat and mouse plasma. 200 
??????????????????????????????????????????????????????????????????????????????????????
phosphate buffer, pH 7.4 to the peripheral chamber of dialysis base plate. The base plate 
was sealed and then incubated at 37oC at 100 rpm on an orbital shaker for 4 h to achieve 
equilibrium. At the end of incubation, the drug concentration was determined in plasma 
and buffer using an LC-MS/MS assay. The free fraction of the drug was calculated as 
ratio of the concentrations in the buffer and in plasma. The results are expressed in terms 
of fraction of drug unbound to plasma proteins (fu).
Microsomal incubations
???????? microsomal metabolic stability of the Lee 1599 was performed in pooled 
?????????? ???????????????????????????????????????? ??????? ????????? stock solution 
of Lee 1599 and 10 mg/mL of microsomal protein solution were prepared in phosphate 
????????????????????????????????????????????? ??????????????????????????????????????
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Figure 5-1. Structure of Lee 1599 
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???????????????????????????????? ?????????????????????????????????????????????
containing 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2 and 1 unit/mL  
glucose-6-phosphate dehydrogenase (BD Biosciences, Woburn, MA). Reaction was 
starte???????????????????????????????????????????????????????????????????? ???????????
incubated at 37°C for 90 minutes. Then the sample was collected and immediately 
quenched by the addition of ice-cold methanol containing an internal standard to stop the 
reaction. The quenched samples were centrifuged and the supernatant was analyzed by 
LC-MS/MS assay to measure the parent compound (Lee 1599) remaining after 90 min of 
incubation period. Verapamil with known significant phase I metabolism was used as 
positive control while deactivated microsomes was used as negative control.
Formulation preparation and administration 
A dosing solution of Lee 1599.2HCl (10 mg/kg) was freshly formulated in water 
(50%) and Plasmalyte A (50%). The IV dose was administered via a femoral vein 
catheter followed by flushing the catheter with saline followed by heparinized glycerol 
locking solution to clear the dead space in the catheter. For subcutaneous administration, 
dosing solution of Lee 1599.2HCl was freshly formulated in water (33.8 %) and 
Plasmalyte A (66.3%) and was administered subcutaneously using a 29 gauge insulin 
syringe. 
Pharmacokinetic studies in rats and mice
The ??????? pharmacokinetic studies presented were performed at the University 
of Tennessee Health Science Center protocol numbers 13-165 and 15-121, approved by 
the Institutional Animal Care and Use Committee of the University of Tennessee Health 
Science Center. Animal studies were conducted according to the guideline of Animal 
Welfare Act and the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals. The animals were kept on a 12 h light/ dark cycle with access to 
food and water ??????????.
Lee 1599 was administered to groups of catheterized (jugular and femoral veins) 
female Sprague-Dawley rats (8–10 weeks old, 200–225 g, n = 6, Harlan BioScience, 
Indianapolis, IN) intravenously at a dose of 10 mg/kg body weight. Thirteen serial blood 
??????????????????????????????????????? ?????????????????????????????????????????????
lithium-heparin via the jugular vein catheter at 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 
24 and 48 h after dosing. Plasma was separated immediately by centrifugation (10,000g 
for 10 min at 4°C) while cumulative urine samples were collected for 48 h. 
Healthy female BALB/c mice (6–8 weeks old, ~20 g) weighing approximately 
20-25 g were obtained from Harlan Bioscience (Indianapolis, IN). Lee 1599 was 
administered to a group of 15 mice by subcutaneous injection at a dose of 200 mg/kg. 
Blood samples were in BD Microtainer plasma separator tubes containing lithium-
heparin collected at 0.083, 0.25, 0.5, 1, 2, 3, 5, 8, 12 and 24 h after administration. Each 
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mouse provided two blood samples, one by a one-time retro-orbital bleed under 
isoflurane anesthesia, and the other by cardiac puncture under isoflurane anesthesia 
followed by euthanasia through cervical dislocation. Plasma was separated immediately 
??????????????????????????????????????????????????????????????????-MS/MS analysis.
Bioanalysis 
Plasma and urine samples were prepared by protein precipitation with methanol 
?????????????????????????????????????-dihydro-??-deoxy-?????-isopropylacetylamino 
spectinomycin) followed by vortexing for 1 min, and then centrifugation at 10,000g for 
10 min at 4°C. The supernatant was se?????????????????????????????????????????????
using high-performance liquid chromatography coupled with tandem mass spectrometry 
(LC-MS/MS). Chromatographic separations were carried out using a Shimadzu Nexera 
XR (LC-20ADXR) liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) 
consisting of two pumps, online degasser, system controller and an autosampler. Liquid 
???????????????????????????????? ???????????????????????????????????? ?????????
(Waters, Milford, MA). The mobile phase was solvent A (water with 1.6% 
nonafluoropentanoic acid and 0.7 % formic acid) and solvent B (90% acetonitrile with 
0.8% nonafluoropentanoic acid and 0.35% formic acid) in the gradient mode as follows: 
0–0.5 min, 20% B; 0.5–1.6 min, 20–90% B; 1.6–2 min, 90% B; 2-2.5 min, 90-20% B, 
2.5–3 min, 20% B at a flow rate of 0.5 mL/min. Analytes were detected with a API 5500 
triple-quadruple mass spectrometer (Applied Biosystems, Foster City, CA) with 
electrospray ionization in multiple reaction monitoring mode using the compound-
specific mass transfers of m/z of 487.2/ 207.1 for Lee 1599 and m/z of 418.3/207.1 for 
Lee 1369. 
Two calibration curves ranging from 1.95 to 2,000 ng/mL and 1.95 to 1000 
μg/mL were constructed and validated with spiked samples of rat and mouse plasma. 
Samples with concentrations above 2000 ng/mL were analyzed with the higher 
calibration range. The peak area ratios of analyte to internal standard was linear over the 
concentration range tested for both compounds, with correlation coefficients (weighted 
least-square linear regression analyses) >0.997. Accuracy (deviation of the analyzed 
quality control samples from nominal values) was within ±3% over the entire range of the 
calibration curve, and precision (coefficient of variation of repeated measurements of the 
quality control samples) was <2%.
Pharmacokinetic data analysis
Naïve data pooling was performed with the mean values of plasma concentrations 
in plasma at each time point plotted against time to generate concentration-time profile. 
The pharmacokinetic parameters were estimated using Phoenix WinNonlin 6.3 (Pharsight 
Corporation, Mountain View, CA) by noncompartmental analysis.  
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Overall strategy for development of the PBPK model for cross-species extrapolation
As a first step, a PBPK model was developed for describing the pharmacokinetics 
of Lee 1599 in rats after IV administration. An independent parameter (cLogP) was 
manually adjusted to optimize the PBPK model with respect to the IV pharmacokinetics 
in rats. Before subsequently predicting the pharmacokinetics in humans, a cross-species 
extrapolation was performed by predicting the pharmacokinetics in mice after SC
administration. Once the optimization of the systemic distribution and clearance of Lee 
1599 had been completed using the rat IV plasma pharmacokinetics as described above, a 
first-order absorption was estimated for SC administration by fitting the model to the 
experimental data obtained from the SC pharmacokinetic study in mice, thereby leaving 
all other drug-specific parameters unchanged and switching the system specific 
parameters from the rat to the mouse species. After evaluating its predictive performance 
in mice, the model was finally used to predict human pharmacokinetics with input for 
human clearance which was scaled from rat clearance. A virtual human population of 100 
individuals was simulated from distributions of anatomical, demographic, and 
physiological variables derived from real patient populations using a Monte Carlo 
simulation approach to account for the variability observed in clinical populations [120]. 
PBPK model structure
The PBPK modeling and simulation was performed using the PK-Sim software 
platform (Version 6.1, Bayer Technology Services GmbH, Leverkusen, Germany) [121]. 
The generic PBPK model structure consists of a series of compartments corresponding to 
different tissues which are connected by the circulation system with a mass balance for 
each compartment [122].
PBPK model parameterizations are broadly categorized into system-specific and 
drug-specific parameters. System-specific physiological parameters such as organ 
volumes, blood flow rates or tissue composition are provided in the software, and were 
originally collected from large numbers of literature sources [123]. 
The second set of parameters required for PBPK models are drug-specific, which 
includes physiochemical data (cLogP, MW and pKa) listed in Table 5-1 and ADME 
properties. cLogP for Lee1599 was estimated using the ChemDraw Ultra software 
(version 11.0, Cambridge Software Company), while the pKa was estimated using 
MarvinSketch 5.10.4 (ChemAxon Lt., Budapest, Hungary). Partition coefficients (Kp) are 
also an important set of compound-specific parameters which determine the distribution 
of the drug into different compartments. The Kp value for each tissue is defined as the 
ratio of total drug exposure in the tissue to the total drug exposure in the plasma at steady 
state. In the past, Kp values had to be determined experimentally by performing extensive 
tissue distribution studies. However, recent development of algorithms based on 
physicochemical and ???????? binding characteristics, including molecular weight, 
lipophilicity and protein binding of the drug, allows prediction of Kp values with 
reasonable degree of accuracy. The PK-Sim software offers several generic algorithms 
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Table 5-1. Physicochemical characteristics of Lee 1599 
Physicochemical parameter Estimate
cLog P -2.5
Molecular Weight (MW) 486.9
pKa 8,10
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for calculation of partition coefficients, and amongst those the distribution model by 
Schmitt was selected for this project. 
 Knowledge about the ADME characteristics of the compound is also vital for 
successful prediction by the model. Clearance is one of the key parameters required for 
PBPK model predictions. For drugs which are predominantly cleared by the liver, the ???
???? clearance is usually extrapolated from ???????? systems including microsomes and 
hepatocytes using physiological scaling factors. However, for the drugs which are renally 
cleared, the ??????? clearance is used as input or it is predicted using allometric scaling 
[116]. Spectinamide antibiotic Lee 1599 is metabolically stable and is nearly exclusively 
cleared by the kidneys via glomerular filtration and active secretion processes. For 
describing the pharmacokinetics of Lee 1599 in rat and mouse, the ??????? clearance was 
used as an input in the PBPK model. In the absence of human pharmacokinetic data, the 
clearance in humans had to be determined by scaling from preclinical species. As renal 
clearance with net active secretion is the main route of elimination for Lee 1599, it 
requires using scaling approaches which are specifically applicable for drugs which are 
predominantly actively secreted in urine. Paine ?????? [124] proposed three different 
approaches for prediction of human renal clearance from preclinical species for drugs that 
exhibit active secretion or net reabsorption. These three approaches are as follows:
Direct correlation method: The renal clearance value in humans is estimated 
from the clearance in rats using the following equation: 
???,?????  = ???, ??? × ?
??,?????
??,???
? × ?????????
??????
?    Eq. 5-1
where CLr,human   and CLr, rat are the renal clearances in human and rat, fu,human and fu,rat
are the unbound fractions in plasma, and KBFhuman (1.3 L/min) [125] and KBFrat (0.0104 
L/min[126] are the respective kidney blood flows. fu has been found to consistent across 
rat, mouse and human for most of the other analogs of spectinamide series [127]. As 
fu,human was not yet available for Lee 1599, it was assumed to be similar to the fu
determined experimentally for Lee 1599 in rat and mouse plasma. 
Simple allometry: The unbound clearance is scaled across preclinical species 
using the following relationship: 
??? = ? × (??)?        Eq. 5-2
where CLr is renal clearance, BW is body weight, and x and y are the coefficient and 
exponent of the allometric equation, respectively. Using this established relationship, the 
human clearance is predicted.
Mahmood’s renal clearance scaling method: The simple allometry method was 
modified by introducing a species scaling factor (SSF) which takes into account the 
physiological differences in kidney between human and preclinical species. 
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??? = ???? ×??? 
??×?? ?        Eq. 5-3
?????????? ?????? = ???????????
????????
?      Eq. 5-4 
where GFR is the glomerular filtration, KBF is the kidney blood flow, and KW is kidney 
weight.  
The first method is single species scaling approach, whereas the latter two 
approaches require IV clearance in at least two preclinical species for extrapolation of 
human clearance. For Lee 1599, IV clearance was only available in rats and therefore, the 
direct correlation method was used for scaling of human clearance.
Results and Discussion
Pharmacokinetics of Lee 1599 in rats and mice 
The concentration-time profile of Lee 1599 displayed bi-exponential decline upon 
IV administration (10 mg/kg) in rats and SC administration (200 mg/kg) in mice. In 
agreement with the theory of allometry, the weight normalized clearance in rats was 
slightly lower than in mice, whereas weight normalized volume of distribution was 
similar in both species (Table 5-2 and Table 5-3). The protein binding was also 
comparable in both species with most of the drug available in unbound form (Table 5-2
& Table 5-3). The fraction of drug eliminated in unchanged form (fe) close to 1 in rats 
and the minimal loss of the parent drug in the ???????? rat microsomal stability study 
strongly suggests that Lee 1599 is predominantly cleared by the renal route. The 
excretion ratio (Eratio) was greater than 1 indicating a net active renal secretion process.
The pharmacokinetics of Lee 1599 was similar to that of its parent compound 
spectinomycin which was also found to be predominantly eliminated by the renal route 
with a total CL of 0.602 L/h/kg in rats. Spectinomycin has a volume of distribution of 
0.756 L/kg which was also comparable to Lee 1599 indicating that it mainly distributes 
into the extracellular body water [66]. 
PBPK model development in rats
A PBPK model for Lee 1599 was developed in rats based after IV administration 
of 10 mg/kg based on the inputs on physicochemical properties listed in Table 5-1 and 
rat specific ADME properties including clearance and protein binding listed in Table 5-2.
The model predicted pharmacokinetic profile in rat was initially unable to 
reasonably describe the distribution phase with under-prediction observed at the lower 
concentrations suggesting poor estimation of partition coefficients (Figure 5-2).  
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Table 5-2. Pharmacokinetic parameters and protein binding of Lee 1599 in rats 
Route Dose 
(mg/kg)
AUCINF
(h·μg/mL)
Vss
(L/kg)
CL
(L/h/kg)
fu Eratio fe
Microsomal 
stability
(% Remaining)
IV 10 15.0 0.467 0.666 0.558 2.76 0.883 100
Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity; Vss:
Volume of distribution at steady state, CL, Total body clearance; fu, Average of the 
fraction of drug unbound to plasma proteins at 0.5 and 5mg/L; fe, Fraction excreted 
unchanged in the urine; Microsomal Stability, % of Lee 1599 remaining after 90 min 
incubation; Eratio, Excretion ratio. 
All values are shown as the means.
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Table 5-3. Pharmacokinetic parameters and protein binding of Lee 1599 in mice 
Route
Dose AUCINF Vz/F CL/F fu
(mg/kg) (h·μg/mL) (L/kg) (L/h/kg)
SC 200 159 0.499 1.25 0.632
Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity; 
VZ/F, Volume of distribution corrected for bioavailability, CL/F, Total body clearance 
corrected for bioavailability; fu, Average of the fraction of drug unbound to plasma 
proteins at 0.5 and 5mg/L; fe, Fraction excreted unchanged in the urine; Microsomal 
Stability, % of Lee 1599 remaining after 90 min incubation; Eratio, Excretion ratio.
All values are shown as the means.
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Figure 5-2. Observed and PBPK model-simulated Lee 1599 total plasma 
concentration-time profile in rats after a single intravenous (IV) dose of 10 mg/kg. 
Solid red line represents simulation result and blue circles represent mean observed data 
with standard error bars.
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 The model was further refined through comparison of PBPK-model predicted and 
observed concentration-time profiles in rat via optimization of partition coefficients 
through manual adjustment of cLogP from -2.5 to -0.50. The rationale for modifying the 
cLogP was based on the premise that software quite often overestimates the 
hydrophilicity of polar compounds. Additionally, the online database ChemDplus 
Advanced (http://chem.sis.nlm.nih.gov/chemidplus) reported a LogP of -0.82 for the 
parent compound spectinomycin, and this supports the modification in the cLogP of Lee 
1599. This change resulted in improved model fits with the predicted parameter values 
within 2 folds of the observed values (Figure 5-3 and Table 5-4) and the final model was 
updated with cLogP of -0.5. 
Application of the PBPK model in mice
The optimized PBPK model developed based on concentration-time data in rats 
was subsequently prospectively tested to predict the Lee 1599 concentration-time profile 
in mice after SC dosing. The clearance and plasma protein binding (fu) were updated with 
the mouse-specific, experimentally determined values (Table 5-3). All other drug-
specific parameters remained unchanged. The absorption phase after SC administration 
was best described by a first-order input to the plasma with an absorption half-life of 13
minutes. Overall, the PBPK model for Lee 1599 optimized in rats was successful in 
explaining its disposition in mice, with all the predicted pharmacokinetic parameters in 
mice within less than 10% deviation of the observed values (Figure 5-4 and Table 5-5).
Scaling of human clearance 
After prospective qualification of the PBPK model in mice, the final step was to 
predict the pharmacokinetics of Lee 1599 in humans. Unlike in the case with the rat and 
mouse model where ??????? clearance was used as an input, for the human PBPK model, 
clearance was predicted using the Direct Correlation Method. Based on this approach, 
human clearance was estimated to be 0.25 L/h/kg. Renal clearance using this approach 
assumes that the renal secretion process remains conserved across species [124]. 
Predictions based on this methodology have been found to correlate well with actual 
clearance parameters in humans, except for certain organic anions for which under-
prediction has been observed because of lower reuptake in human kidneys relative to rats 
[124]. Additionally, gender differences in urinary excretion have also been reported in 
rats for substrates of organic anion-transporting polypeptide 1 (oatp1) with higher 
clearance in females as compared to male rats [128]. Studies are underway to further 
characterize the transporters involved in the active secretion of Lee 1599, and its relative 
expression in different preclinical species and humans. 
The predicted human CL of Lee 1599 was within two folds of the spectinomycin 
CL of 0.104 L/h/kg which was observed after IV administration of spectinomycin in 
healthy volunteers [129]. It is also important to acknowledge, however that as the human 
clearance prediction was based only upon one species, there is substantial uncertainty  
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Figure 5-3. Observed and refined PBPK model-simulated Lee 1599 total plasma 
concentration-time profile in rat after a single intravenous (IV) dose of 10 mg/kg 
Solid red line represents simulation result and blue circles represent mean observed data 
with standard error bars.
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Table 5-4. Comparison of observed versus PBPK model predicted 
pharmacokinetic parameters of Lee 1599 in rats after a single intravenous (IV) dose 
of 10 mg/kg 
Parameter Observed Predicted
Ratio of
observed / predicted
AUCINF (h·μg/mL) 15.0 15.0 1
Vss (L/kg) 0.467 0.441 1.06
CL (L/h/kg) 0.666 0.666 1
Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity; Vss:
Volume of distribution at steady state, CL, Total body clearance. 
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Figure 5-4. Observed and PBPK model-simulated Lee 1599 total plasma 
concentration-time profile in mice after a single subcutaneous (SC) dose of 200 
mg/kg
Solid red line represents simulation result and blue circles represent mean observed data 
with standard error bars. 
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Table 5-5. Comparison of observed versus PBPK model predicted 
pharmacokinetic parameters of Lee 1599 in mice after a single subcutaneous (SC) 
dose of 200mg/kg 
Parameter Observed Predicted
Ratio of 
observed / predicted
AUCINF (h·μg/mL) 159 168 0.946
Vz /F(L/kg) 0.499 0.541 0.922
CL/F (L/h/kg) 1.25 1.19 1.05
Abbreviations: AUCINF: Area under the curve from time zero extrapolated to infinity; 
VZ/F, Volume of distribution corrected for bioavailability, CL/F, Total body clearance 
corrected for bioavailability.
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associated with it. As the development of Lee 1599 gradually progresses into the late 
discovery phase, additional pharmacokinetic data will become available in other pre-
clinical species like dogs, which in combination with the existing data could be used for 
making a more confident prediction. 
Prediction of human pharmacokinetics
Using the human clearance estimate from the Direct Correlation Method along 
with an assumed fu of 0.55 (similar to rat and mice fu) in humans, and all other drug 
specific parameters unchanged, the PBPK model was used to predict the human 
pharmacokinetics (Figure 5-5). The parameters for the simulated virtual pharmacokinetic 
profile in humans for dose of 7.5 and 27.5 mg/kg are listed in Table 5-6. In agreement 
with the theory of allometry, the predicted weight normalized clearance as well as 
volume of distribution were lower than those found in rats and mice. 
Based on this model, a dose of 7.5 and 27.5 mg/kg administered once daily via IV 
administration will be required to attain similar exposure as observed in mice after SC
administration of 50 mg/kg and 200 mg/kg respectively. This dose range was selected 
based on the results of the dose-exposure-response analysis of Lee 1810, a structural 
analog of Lee 1599 and a competing lead candidate, which suggested that reasonable 
efficacy could be attained within a dose range of 50 mg/kg – 200 mg/kg, dependent on 
the dosing interval. The feasibility of achieving the projected dose range of Lee 1599 in 
humans is supported by similar dose recommendation for the parent compound 
spectinomycin, which is prescribed as single-dose treatment of 2 g spectinomycin 
administered by intramuscular injection for the treatment of gonococcal infections and 
other associated conditions [130]. Going forward, the exposure differences in mice for 
different routes of administration and health status would also need to be studied in order 
to obtain a more precise prediction of the efficacious dose range in humans. Additionally, 
the dose projection was based on the premise that Lee 1599 will be used as a single agent. 
However, in the clinic Lee 1599 will likely be used in combination with other anti-
tuberculosis agents, which is assumed to result in a lower dose requirement for Lee 1599.
In summary, the pharmacokinetics of Lee 1599 was described by a PBPK model 
in rats and mice, and the model was applied to predict the pharmacokinetics and dose 
requirements of Lee 1599 in humans. This model suggests that an efficacious systemic 
exposure can be achieved with daily doses feasible in humans, and may be useful during 
drug development for understanding the dose requirements of future preclinical and 
clinical studies.
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Figure 5-5. Simulated time course of Lee 1599 total plasma concentration after 
intravenous (IV) dose of 7.5 (top) and 27.5 mg/kg (bottom) in a virtual population 
human
The solid red line represents the median and the red band represents the range 5% to 95% 
for the 100 simulated profiles in a virtual human population. 
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Table 5-6. Model predicted pharmacokinetic parameters of Lee 1599 in humans 
after intravenous (IV) dose of 7.5 and 27.5 mg/kg, which results in a similar 
exposure after subcutaneous (SC) injection in mice of 50 and 200 mg/kg respectively
Dose Parameter 
Lower
5%
range
Median
Upper
95% 
range
7.5 mg/kg Cmax (μg/mL) 34.6 41.2 56.2
AUCINF (h·μg/mL) 15 26.6 50.8
Vss (L/kg) 0.322 0.254 0.239
CL (L/h/kg) 0.499 0.282 0.148
27.5 mg/kg Cmax (μg/mL) 160 165 206
AUCINF (h·μg/mL) 55.1 97.6 186
Vss (L/kg) 0.322 0.254 0.239
CL (L/h/kg) 0.499 0.282 0.148
Abbreviations: Cmax, Peak concentration, AUCINF: Area under the curve from time zero 
extrapolated to infinity; Vss: Volume of distribution at steady state, CL, Total body 
clearance.
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CHAPTER 6.   ?SUMMARY
The antibiotic spectinomycin is a bacterial protein synthesis inhibitor with a 
distinct mechanism of action and a high safety margin, but it is ineffective against 
?????????????????????????? (???). Using structure-based design, a novel class of amide 
derivatives of spectinomycin was generated with potent antitubercular activity which 
blocks native efflux from the tuberculosis cell. I hypothesized that the application of 
translational PK/PD approaches would facilitate further development of the lead 
compounds Lee 1599 and Lee 1810. 
To identify the main driver for efficacy of lead spectinamide Lee 1810, a dose-
fractionation study was performed in BALB/c mice infected with a low dose aerosol of 
??? which were treated with different dosing regimens of Lee 1810. Dosing was 
continued for 4 weeks with blood sampling at 0.25 h and 8 h post dose from each mice in 
the last week, followed by a washout period after which the mice were sacrificed and the 
lungs removed for measurement of colony forming units (CFU). The concentrations at 
0.25 h increased in a dose-proportional fashion until 100 mg/kg and then increased more 
than dose-proportional between 200 – 400 mg/kg. However, concentrations at 8 h were 
found to be dose-proportional across the entire dose range. A simultaneous population 
pharmacokinetic analysis of sparse data from the dose-fractionation study and intensive 
data from a pharmacokinetic study in healthy mice was performed using nonlinear mixed 
effects modeling. A two-compartment model with first-order absorption and linear 
elimination from the central compartment characterized the plasma concentration–time 
profile of Lee 1810. The nonlinearity in C0.25 above 100 mg/kg was described using a 
higher absorption rate for those dose levels and can potentially be explained by an 
increased absorption rate associated with faster diffusion at the subcutaneous site of 
administration. Healthy mice had 56.5 % lower clearance, 69% lower volume of 
distribution of the central compartment and 69.6 % lower intercompartmental clearance
as compared to infected mice. These differences could be a result of differences in 
plasma binding protein concentrations, an altered hydration status in infected animal, 
and/or altered hemodynamics in this chronic disease state.  
A two-subpopulation natural bacterial growth model adequately described the 
dynamic change in bacterial count in the untreated group of mice plus data obtained from 
previously performed studies and from the literature. ??? is a slow growing bacterium 
with a growth rate constant Krep estimated by the model as 0.0327 h
-1, which is within the 
range of growth rate constants found in the literature. To account for the bacterial kill by 
the immune system of mice, a first-order death rate constant (Kir) was introduced for both 
of the subpopulations.  
A sequential PK/PD analysis was performed by integrating the individual ?????
??? parameter estimates from the population pharmacokinetic analysis with the bacterial 
growth model via an exposure-dependent bacterial kill function characterized by a 
sigmoid Emax model for describing the overall rate of change in lung CFU with different 
dosing regimens. The PK/PD model could reasonably describe the microbial kill of Lee 
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1810 with EC50, Emax and ? estimated as 239 μg/mL, 11.9 h-1 and 2.40, respectively. A 
high value of the Hill coefficient is a typical characteristic observed for other 
concentration-dependent killing antibiotics. EC50 (239 μg/mL) was found to be much 
higher than MIC (1.6 μg/mL) of Lee 1810. EC50 describes the time course of drug effect 
and is much more realistic parameter to compare potency of compounds rather than the 
MIC, which represents the lowest static concentration at which no growth of 
microorganism is visible to the naked eye. Lee 1810 demonstrated concentration-
dependent antibacterial kill which suggests that the higher the peak concentration is 
above MIC, the better would be the microbial kill. Although Lee 1810 has a short half-
life, its concentration–dependent killing characteristics and moderate ???????? post 
antibiotic effect of 20 h support its intermittent dosing which is also commonly used for 
aminoglycoside antibiotics.  
Spectinamides are highly water soluble and poorly permeable resulting in limited 
oral bioavailability and hence are usually administered through the subcutaneous route in 
mice. Additionally, since the lungs are the main organ affected in pulmonary 
tuberculosis, the efficacy of Lee 1599 was evaluated after IT administration in a mouse 
model of ??? infection. The results of this study suggest significantly improved efficacy 
compared to SC administration. Based on these observations, I hypothesized that IT 
delivery of Lee 1599 has better efficacy compared to SC administration in mice due to 
higher concentrations of drug at the site of infection in the lungs for a longer duration of 
time. This hypothesis was tested by comparing the biodistribution of Lee 1599 in vital 
organs, including the lungs, in mice with both routes of administration. The rate and 
extent of absorption was almost two times higher with IT as compared to SC 
administration. This can be explained by the natural capacity of lungs to allow 
permeation of small molecules, and it also suggests that the drug is likely being delivered 
to the peripheral regions of the lungs which is desirable as ??? usually resides in these 
regions. As expected, highest exposure of Lee 1599 after IT administration was attained 
in the lungs which was 2.5 times higher than in plasma. Dibasic compounds including 
Lee 1599 usually have longer lung retention which may be explained by the phenomena 
of ‘lysosomal trapping’ where the basic drug gets accumulated in the acidic compartment 
of lysosomes of alveolar macrophages and acts as a reservoir. Even though Lee 1599 is 
highly hydrophilic, it was found to slightly accumulate in tissues such as liver and kidney 
suggesting the potential role of transporters involved in the uptake into cells in these 
organs. Overall, this study supports the pulmonary route as a potential pathway for the 
treatment of tuberculosis with Lee 1599. 
The projection of human pharmacokinetics from preclinical species is one of the 
most challenging steps in drug development. Physiologically-based pharmacokinetic 
(PBPK) modelling is an approach which has recently gained importance for cross-species 
extrapolation of pharmacokinetics. It utilizes the anatomical and physiological parameters 
of the species along with the drug-specific inputs obtained by ?????????/???????
extrapolation or ????????/??????? extrapolation for prediction of pharmacokinetics. My 
objective was to develop a PBPK model for describing the pharmacokinetics of Lee 1599 
in rats and mice, and perform human pharmacokinetics predictions in order to address the 
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hypothesis that systemic exposures efficacious in mice are feasible to be achieved in 
humans. 
The pharmacokinetics of Lee 1599 in rats were well described by the optimized 
PBPK model. The predicted systemic exposure, clearance and volume of distribution 
were within 10% of their observed values. The model was subsequently qualified by 
reasonably predicting murine pharmacokinetic behavior. The subsequently predicted, 
dose normalized human clearance and volume of distribution were as expected lower 
than those found in rats and mice. An IV dose of 7.5 mg/kg and 27.5 mg/kg administered 
once daily was predicted to match the efficacious exposure observed in mice after SC
administration of 50 mg/kg and 200 mg/kg respectively, and appears to be achievable in 
patients. 
In conclusion, translational PK/PD approaches have been successfully used for 
further the further development and characterization of the spectinamide lead compounds 
Lee 1599 and Lee 1810. The results from the above studies will be helpful in identifying 
and optimizing dosing regimens which can strike a balance between bacterial count 
reduction, adverse effects, and emergence of resistance. Pulmonary delivery offers an 
innovative solution to overcome the limitation of poor oral bioavailability of 
spectinamides, and also opens up new opportunities to further improve efficacy. PBPK-
modeling based interspecies scaling suggests that therapeutically effective exposures can 
be achieved with doses that are feasible to be administered to humans.
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